1
|
Zhu F, Zhao Y, Arnold DL, Bar‐Or A, Bernstein CN, Bonner C, Graham M, Hart J, Knox N, Marrie RA, Mirza AI, O'Mahony J, Van Domselaar G, Yeh EA, Banwell B, Waubant E, Tremlett H. A cross-sectional study of MRI features and the gut microbiome in pediatric-onset multiple sclerosis. Ann Clin Transl Neurol 2024; 11:486-496. [PMID: 38130033 PMCID: PMC10863907 DOI: 10.1002/acn3.51970] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Revised: 10/27/2023] [Accepted: 11/24/2023] [Indexed: 12/23/2023] Open
Abstract
OBJECTIVE To identify gut microbiome features associated with MRI lesion burden in persons with pediatric-onset multiple sclerosis (symptom onset <18 years). METHODS A cross-sectional study involving the Canadian Paediatric Demyelinating Disease Network study participants. Gut microbiome features (alpha diversity, phylum- and genus-level taxa) were derived using 16S rRNA sequencing from stool samples. T1- and T2-weighted lesion volumes were measured on brain MRI obtained within 6 months of stool sample procurement. Associations between the gut microbiota and MRI metrics (cube-root-transformed) were assessed using standard and Lasso regression models. RESULTS Thirty-four participants were included; mean ages at symptom onset and MRI were 15.1 and 19.0 years, respectively, and 79% were female. The T1- and T2-weighted lesion volumes were not significantly associated with alpha diversity (age and sex-adjusted p > 0.08). At the phylum level, high Tenericutes (relative abundance) was associated with higher T1 and T2 volumes (β coefficient = 0.25, 0.37) and high Firmicutes, Patescibacteria or Actinobacteria with lower lesion volumes (β coefficient = -0.30 to -0.07). At the genus level, high Ruminiclostridium, whereas low Coprococcus 3 and low Erysipelatoclostridium were associated with higher lesion volumes. INTERPRETATION Our study characterized the gut microbiota features associated with MRI lesion burden in pediatric-onset MS, shedding light onto possible pathophysiological mechanisms.
Collapse
Affiliation(s)
- Feng Zhu
- Department of Medicine (Neurology)The University of British ColumbiaVancouverBritish ColumbiaCanada
| | - Yinshan Zhao
- Department of Medicine (Neurology)The University of British ColumbiaVancouverBritish ColumbiaCanada
| | - Douglas L. Arnold
- Department of Neurology and NeurosurgeryMcGill University Faculty of MedicineMontrealQuebecCanada
| | - Amit Bar‐Or
- Department of Neurology, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
- The Children's Hospital of PhiladelphiaPhiladelphiaPennsylvaniaUSA
| | - Charles N. Bernstein
- Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health SciencesUniversity of ManitobaWinnipegManitobaCanada
- Inflammatory Bowel Disease Clinical and Research CentreUniversity of ManitobaWinnipegManitobaCanada
| | - Christine Bonner
- National Microbiology LaboratoryPublic Health Agency of CanadaWinnipegManitobaCanada
| | - Morag Graham
- National Microbiology LaboratoryPublic Health Agency of CanadaWinnipegManitobaCanada
- Department of Medical Microbiology and Infectious DiseasesUniversity of ManitobaWinnipegManitobaCanada
| | - Janace Hart
- Department of NeurologyUniversity of California San FranciscoSan FranciscoCaliforniaUSA
| | - Natalie Knox
- National Microbiology LaboratoryPublic Health Agency of CanadaWinnipegManitobaCanada
- Department of Medical Microbiology and Infectious DiseasesUniversity of ManitobaWinnipegManitobaCanada
| | - Ruth Ann Marrie
- Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health SciencesUniversity of ManitobaWinnipegManitobaCanada
| | - Ali I. Mirza
- Department of Medicine (Neurology)The University of British ColumbiaVancouverBritish ColumbiaCanada
| | - Julia O'Mahony
- Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health SciencesUniversity of ManitobaWinnipegManitobaCanada
| | - Gary Van Domselaar
- National Microbiology LaboratoryPublic Health Agency of CanadaWinnipegManitobaCanada
- Department of Medical Microbiology and Infectious DiseasesUniversity of ManitobaWinnipegManitobaCanada
| | - E. Ann Yeh
- Department of Neurology and NeurosurgeryMcGill University Faculty of MedicineMontrealQuebecCanada
| | - Brenda Banwell
- Department of Neurology, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA
- The Children's Hospital of PhiladelphiaPhiladelphiaPennsylvaniaUSA
| | - Emmanuelle Waubant
- Department of NeurologyUniversity of California San FranciscoSan FranciscoCaliforniaUSA
| | - Helen Tremlett
- Department of Medicine (Neurology)The University of British ColumbiaVancouverBritish ColumbiaCanada
| | | |
Collapse
|
2
|
Butel-Simoes G, Kua H, Safdar A, Graham M, Korman T, Meher-Homji Z. Cryptococcal laryngitis in an immunocompetent asthmatic patient using inhaled corticosteroids. Med Mycol Case Rep 2023; 42:100599. [PMID: 37727452 PMCID: PMC10506085 DOI: 10.1016/j.mmcr.2023.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2023] [Revised: 08/07/2023] [Accepted: 08/15/2023] [Indexed: 09/21/2023] Open
Abstract
We present a case of laryngeal cryptococcosis caused by cryptococcosis neoformans var. grubii affecting a patient using excessive inhaled corticosteroids. The patient experienced symptoms for several months prior to specialist review and the visualization of a mass lesion by nasopharyngoscopy. Fortunately a biopsy was performed and through histopathology & microbiological assessment a diagnosis of cryptococcal laryngitis was made. Treatment with 6 months of fluconazole resulted in clinical cure and resolution of symptoms. It is important to raise awareness of the risk of non-Candida fungal infections in patients on high dose corticosteroids, especially in the post covid era were steroids are more commonly prescribed.
Collapse
Affiliation(s)
- G.I. Butel-Simoes
- Monash Infectious Diseases and Microbiology, Monash Health, Victoria, Australia
| | - H. Kua
- Department of Anatomical Pathology, Monash Health, Victoria, Australia
| | - A. Safdar
- Department of Otolaryngology/ Head and Neck Surgery, Monash Health Victoria, Australia
| | - M. Graham
- Monash Infectious Diseases and Microbiology, Monash Health, Victoria, Australia
- Monash University, Clayton, Victoria, Australia
| | - T. Korman
- Monash Infectious Diseases and Microbiology, Monash Health, Victoria, Australia
- Monash University, Clayton, Victoria, Australia
| | - Z. Meher-Homji
- Department of Infectious Diseases, Latrobe Regional Hospital, Victoria, Australia
| |
Collapse
|
3
|
Rumore J, Walker M, Pagotto F, Forbes JD, Peterson CL, Tyler AD, Graham M, Van Domselaar G, Nadon C, Reimer A, Knox N. Use of a taxon-specific reference database for accurate metagenomics-based pathogen detection of Listeria monocytogenes in turkey deli meat and spinach. BMC Genomics 2023; 24:361. [PMID: 37370007 DOI: 10.1186/s12864-023-09338-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2022] [Accepted: 04/26/2023] [Indexed: 06/29/2023] Open
Abstract
BACKGROUND The reliability of culture-independent pathogen detection in foods using metagenomics is contingent on the quality and composition of the reference database. The inclusion of microbial sequences from a diverse representation of taxonomies in universal reference databases is recommended to maximize classification precision for pathogen detection. However, these sizable databases have high memory requirements that may be out of reach for some users. In this study, we aimed to assess the performance of a foodborne pathogen (FBP)-specific reference database (taxon-specific) relative to a universal reference database (taxon-agnostic). We tested our FBP-specific reference database's performance for detecting Listeria monocytogenes in two complex food matrices-ready-to-eat (RTE) turkey deli meat and prepackaged spinach-using three popular read-based DNA-to-DNA metagenomic classifiers: Centrifuge, Kraken 2 and KrakenUniq. RESULTS In silico host sequence removal led to substantially fewer false positive (FP) classifications and higher classification precision in RTE turkey deli meat datasets using the FBP-specific reference database. No considerable improvement in classification precision was observed following host filtering for prepackaged spinach datasets and was likely a consequence of a higher microbe-to-host sequence ratio. All datasets classified with Centrifuge using the FBP-specific reference database had the lowest classification precision compared to Kraken 2 or KrakenUniq. When a confidence-scoring threshold was applied, a nearly equivalent precision to the universal reference database was achieved for Kraken 2 and KrakenUniq. Recall was high for both reference databases across all datasets and classifiers. Substantially fewer computational resources were required for metagenomics-based detection of L. monocytogenes using the FBP-specific reference database, especially when combined with Kraken 2. CONCLUSIONS A universal (taxon-agnostic) reference database is not essential for accurate and reliable metagenomics-based pathogen detection of L. monocytogenes in complex food matrices. Equivalent classification performance can be achieved using a taxon-specific reference database when the appropriate quality control measures, classification software, and analysis parameters are applied. This approach is less computationally demanding and more attainable for the broader scientific and food safety communities.
Collapse
Affiliation(s)
- Jillian Rumore
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada.
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada.
| | - Matthew Walker
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada
| | - Franco Pagotto
- Food Directorate, Health Canada, Bureau of Microbial Hazards, Ottawa, ON, Canada
| | - Jessica D Forbes
- Eastern Ontario Regional Laboratory Association, Ottawa, ON, Canada
| | - Christy-Lynn Peterson
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada
| | - Andrea D Tyler
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada
| | - Morag Graham
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada
| | - Gary Van Domselaar
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada
| | - Celine Nadon
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada
| | - Aleisha Reimer
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada
| | - Natalie Knox
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
- Public Health Agency of Canada, National Microbiology Laboratory, MB, Winnipeg, Canada
| |
Collapse
|
4
|
Grant JR, Enns E, Marinier E, Mandal A, Herman EK, Chen CY, Graham M, Van Domselaar G, Stothard P. Proksee: in-depth characterization and visualization of bacterial genomes. Nucleic Acids Res 2023:7151341. [PMID: 37140037 DOI: 10.1093/nar/gkad326] [Citation(s) in RCA: 121] [Impact Index Per Article: 121.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 03/28/2023] [Accepted: 04/18/2023] [Indexed: 05/05/2023] Open
Abstract
Proksee (https://proksee.ca) provides users with a powerful, easy-to-use, and feature-rich system for assembling, annotating, analysing, and visualizing bacterial genomes. Proksee accepts Illumina sequence reads as compressed FASTQ files or pre-assembled contigs in raw, FASTA, or GenBank format. Alternatively, users can supply a GenBank accession or a previously generated Proksee map in JSON format. Proksee then performs assembly (for raw sequence data), generates a graphical map, and provides an interface for customizing the map and launching further analysis jobs. Notable features of Proksee include unique and informative assembly metrics provided via a custom reference database of assemblies; a deeply integrated high-performance genome browser for viewing and comparing analysis results at individual base resolution (developed specifically for Proksee); an ever-growing list of embedded analysis tools whose results can be seamlessly added to the map or searched and explored in other formats; and the option to export graphical maps, analysis results, and log files for data sharing and research reproducibility. All these features are provided via a carefully designed multi-server cloud-based system that can easily scale to meet user demand and that ensures the web server is robust and responsive.
Collapse
Affiliation(s)
- Jason R Grant
- Agriculture, Food & Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2P5, Canada
| | - Eric Enns
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
| | - Eric Marinier
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
| | - Arnab Mandal
- Medical Microbiology & Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
| | - Emily K Herman
- Agriculture, Food & Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2P5, Canada
| | - Chih-Yu Chen
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
- Biochemistry & Medical Genetics, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
| | - Morag Graham
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
- Medical Microbiology & Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
| | - Gary Van Domselaar
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba R3E 3R2, Canada
- Medical Microbiology & Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
| | - Paul Stothard
- Agriculture, Food & Nutritional Science, University of Alberta, Edmonton, Alberta T6G 2P5, Canada
| |
Collapse
|
5
|
Harrison LB, Bergeron G, Cadieux G, Charest H, Fafard J, Levade I, Blais AC, Huchet E, Trottier B, Vlad D, Szabo J, Thomas R, Poulin S, Greenaway C, Zaharatos GJ, Oughton M, Chakravarti A, Pilarski R, Bui-Nguyen A, Benomar K, Libman MD, Vinh DC, Duggan AT, Graham M, Klein MB, Barkati S. Monkeypox in Montréal: Epidemiology, Phylogenomics, and Public Health Response to a Large North American Outbreak. Ann Intern Med 2023; 176:67-76. [PMID: 36508736 DOI: 10.7326/m22-2699] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Monkeypox, a viral zoonotic disease, is causing a global outbreak outside of endemic areas. OBJECTIVE To characterize the outbreak of monkeypox in Montréal, the first large outbreak in North America. DESIGN Epidemiologic and laboratory surveillance data and a phylogenomic analysis were used to describe and place the outbreak in a global context. SETTING Montréal, Canada. PATIENTS Probable or confirmed cases of monkeypox. MEASUREMENTS Epidemiologic, clinical, and demographic data were aggregated. Whole-genome sequencing and phylogenetic analysis were performed for a set of outbreak sequences. The public health response and its evolution are described. RESULTS Up to 18 October 2022, a total of 402 cases of monkeypox were reported mostly among men who have sex with men (MSM), most of which were suspected to be acquired through sexual contact. All monkeypox genomes nested within the B.1 lineage. Montréal Public Health worked closely with the affected communities to control the outbreak, becoming the first jurisdiction to offer 1 dose of the Modified Vaccinia Ankara-Bavarian Nordic vaccine as preexposure prophylaxis (PrEP) to those at risk in early June 2022. Two peaks of cases were seen in early June and July (43 and 44 cases per week, respectively) followed by a decline toward near resolution of the outbreak in October. Reasons for the biphasic peak are not fully elucidated but may represent the tempo of vaccination and/or several factors related to transmission dynamics and case ascertainment. LIMITATIONS Clinical data are self-reported. Limited divergence among sequences limited genomic epidemiologic conclusions. CONCLUSION A large outbreak of monkeypox occurred in Montréal, primarily among MSM. Successful control of the outbreak rested on early and sustained engagement with the affected communities and rapid offer of PrEP vaccination to at-risk persons. PRIMARY FUNDING SOURCE None.
Collapse
Affiliation(s)
- Luke B Harrison
- Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, Montréal, Québec, Canada (L.B.H.)
| | - Geneviève Bergeron
- Direction régionale de santé publique de Montréal, Montréal, Québec, Canada (G.B.)
| | - Geneviève Cadieux
- Direction régionale de santé publique de Montréal and Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada (G.C.)
| | - Hugues Charest
- Laboratoire de santé publique du Québec, INSPQ, Sainte-Anne-de-Bellevue, and Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, Québec, Canada (H.C., J.F.)
| | - Judith Fafard
- Laboratoire de santé publique du Québec, INSPQ, Sainte-Anne-de-Bellevue, and Département de microbiologie, infectiologie et immunologie, Université de Montréal, Montréal, Québec, Canada (H.C., J.F.)
| | - Inès Levade
- Laboratoire de Santé publique du Québec, INSPQ, Sainte-Anne-de-Bellevue, Québec, Canada (I.L.)
| | | | | | - Benoît Trottier
- Clinique Médicale du Quartier Latin, Montréal, Québec, Canada (B.T., D.V.)
| | - Dragos Vlad
- Clinique Médicale du Quartier Latin, Montréal, Québec, Canada (B.T., D.V.)
| | - Jason Szabo
- Clinique Médicale l'Actuel, Montréal, Québec, Canada (J.S., R.T.)
| | - Réjean Thomas
- Clinique Médicale l'Actuel, Montréal, Québec, Canada (J.S., R.T.)
| | | | - Christina Greenaway
- Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Department of Medicine, Division of Infectious Diseases, Jewish General Hospital, and J.D. MacLean Centre for Tropical Diseases at McGill University, Montréal, Québec, Canada (C.G.)
| | - Gerasimos J Zaharatos
- Department of Medicine, Division of Infectious Diseases, Jewish General Hospital, Montréal, Québec, Canada (G.J.Z., M.O.)
| | - Matthew Oughton
- Department of Medicine, Division of Infectious Diseases, Jewish General Hospital, Montréal, Québec, Canada (G.J.Z., M.O.)
| | - Arpita Chakravarti
- Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada (A.C.)
| | - Robert Pilarski
- Clinique Médicale La Licorne, Montréal, Québec, Canada (R.P.)
| | | | | | - Michael D Libman
- Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, J.D. MacLean Centre for Tropical Diseases at McGill University, and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada (M.D.L., S.B.)
| | - Donald C Vinh
- Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada (D.C.V.)
| | - Ana T Duggan
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada (A.T.D.)
| | - Morag Graham
- National Microbiology Laboratory, Public Health Agency of Canada, and Department of Medical Microbiology & Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada (M.G.)
| | - Marina B Klein
- Department of Medicine, Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre, and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada (M.B.K.)
| | - Sapha Barkati
- Department of Medicine, Division of Infectious Diseases, McGill University Health Centre, J.D. MacLean Centre for Tropical Diseases at McGill University, and Research Institute of the McGill University Health Centre, Montréal, Québec, Canada (M.D.L., S.B.)
| |
Collapse
|
6
|
Tuohy D, Cassidy I, Carey E, Graham M, McCarthy J, Murphy J, Morrissey K, Shanahan J, Tuohy T. 183 DEVELOPING AND FACILITATING ONLINE INTERGENERATIONAL CAFÉS. Age Ageing 2022. [DOI: 10.1093/ageing/afac218.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Many older people throughout their lives will require nursing care, consequentially most nurses will care for older people during their career. It is important that older people and student nurses are provided with shared learning opportunities so that professional caring partnerships can be nurtured and realised for mutual benefit. Intergenerational projects offer opportunities for intergenerational learning. However, few projects explore student nurse-older person dyads and how these can be integrated within undergraduate pre-registration programmes. This paper describes the development and facilitation of online older person-student nurse intergenerational cafés.
Methods
The project was managed by a design team comprising senior administration, lecturers in BSc Nursing programmes and a lecturer in Design for Health and Wellbeing. The ‘world café’ concept along with values of enablement and participation underpinned the design. The initiative was planned to align with a year three community care module. Regular online team meetings were held to agree the aims and outcomes for student nurse-older person cohorts, decide recruitment strategies, agree the process and format of facilitation. Older people were recruited through retirement, church, volunteer, social and sporting organisations, media and also using snowballing methods.
Results
Both student nurse and older person cohorts were offered support on how to access and participate in the café. Participants attended one of three online cafés hosted through Microsoft Teams. Each café followed the same format: 1) Group meeting convened with all participants; 2) Breakout small group ‘table’ discussions with student nurse-older people participants and design team facilitation; 3) The café was reconvened to whole group meeting where feedback was collated to elicit shared learning.
Conclusion
The initiative proved successful and there is merit in embedding intergenerational cafés into professionally accredited health care programmes. Through sharing life experiences and perspectives, intergenerational barriers can be reduced and new insights developed on person-centred gerontological care.
Collapse
Affiliation(s)
- D Tuohy
- University of Limerick , Limerick, Ireland
| | - I Cassidy
- University of Limerick , Limerick, Ireland
| | - E Carey
- University of Limerick , Limerick, Ireland
| | - M Graham
- University of Limerick , Limerick, Ireland
| | - J McCarthy
- University of Limerick , Limerick, Ireland
| | - J Murphy
- University of Limerick , Limerick, Ireland
| | | | - J Shanahan
- University of Limerick , Limerick, Ireland
| | - T Tuohy
- University of Limerick , Limerick, Ireland
| |
Collapse
|
7
|
Kumbhare SV, Jones WD, Fast S, Bonner C, Jong G‘, Van Domselaar G, Graham M, Narvey M, Azad MB. Source of human milk (mother or donor) is more important than fortifier type (human or bovine) in shaping the preterm infant microbiome. Cell Rep Med 2022; 3:100712. [PMID: 36029771 PMCID: PMC9512671 DOI: 10.1016/j.xcrm.2022.100712] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2021] [Revised: 04/13/2022] [Accepted: 07/14/2022] [Indexed: 12/20/2022]
Abstract
Milk fortifiers help meet the nutritional needs of preterm infants receiving their mother’s own milk (MOM) or donor human milk. We conducted a randomized clinical trial (NCT03214822) in 30 very low birth weight premature neonates comparing bovine-derived human milk fortifier (BHMF) versus human-derived fortifier (H2MF). We found that fortifier type does not affect the overall microbiome, although H2MF infants were less often colonized by an unclassified member of Clostridiales Family XI. Secondary analyses show that MOM intake is strongly associated with weight gain and microbiota composition, including Bifidobacterium, Veillonella, and Propionibacterium enrichment. Finally, we show that while oxidative stress (urinary F2-isoprostanes) is not affected by fortifier type or MOM intake, fecal calprotectin is higher in H2MF infants and lower in those consuming more MOM. Overall, the source of human milk (mother versus donor) appears more important than the type of milk fortifier (human versus bovine) in shaping preterm infant gut microbiota. Milk fortifier type (human versus bovine) has little impact on the preterm microbiome Milk source (mother versus donor) is strongly associated with microbiome composition Feeding mother’s own milk is linked to better weight gain and less gut inflammation
Collapse
|
8
|
Mirza AI, Zhu F, Knox N, Forbes JD, Bonner C, Van Domselaar G, Bernstein CN, Graham M, Marrie RA, Hart J, Yeh EA, Arnold DL, Bar-Or A, O'Mahony J, Zhao Y, Hsiao W, Banwell B, Waubant E, Tremlett H. The metabolic potential of the paediatric-onset multiple sclerosis gut microbiome. Mult Scler Relat Disord 2022; 63:103829. [DOI: 10.1016/j.msard.2022.103829] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Revised: 03/23/2022] [Accepted: 04/21/2022] [Indexed: 11/16/2022]
|
9
|
Graham M, Sproule C, Sharma M, Likinyo H, Glackin K, Hurrell D, Khalil A, Mone F. Spontaneous maternal coagulopathy in COVID-19. Ultrasound Obstet Gynecol 2022; 59:558-560. [PMID: 35025134 DOI: 10.1002/uog.24859] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Revised: 01/04/2022] [Accepted: 01/05/2022] [Indexed: 06/14/2023]
Affiliation(s)
- M Graham
- Southern Health and Social Care Trust, UK
| | - C Sproule
- Royal Jubilee Maternity Service, Belfast Health and Social Care Trust, Belfast, UK
| | - M Sharma
- Royal Jubilee Maternity Service, Belfast Health and Social Care Trust, Belfast, UK
| | - H Likinyo
- Southern Health and Social Care Trust, UK
| | - K Glackin
- Western Health and Social Care Trust, UK
| | - D Hurrell
- Pathology Department, Alder Hey Children's Hospital, Liverpool, UK
| | - A Khalil
- Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK
- Fetal Medicine Unit, St George's University Hospitals, NHS Foundation Trust, University of London, London, UK
| | - F Mone
- Centre for Public Health, Queen's University Belfast, Belfast, UK
| |
Collapse
|
10
|
Liang G, Zhu F, Mirza AI, Bar-Or A, Bernstein CN, Bonner C, Forbes JD, Graham M, Hart J, Knox NC, Marrie RA, O'Mahony J, Van Domselaar G, Yeh EA, Zhao Y, Banwell B, Waubant E, Tremlett H. Stability of the gut microbiota in persons with paediatric-onset multiple sclerosis and related demyelinating diseases. Mult Scler 2022; 28:1819-1824. [PMID: 35296164 PMCID: PMC9442770 DOI: 10.1177/13524585221079533] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Objective: Examine if the gut microbiota composition changes across repeated samples in
paediatric-onset multiple sclerosis (MS) or monophasic-acquired
demyelinating syndromes (monoADS). Methods: A total of 36 individuals (18 MS/18 monoADS) with ⩾2 stool samples were
included. Stool sample-derived DNA was sequenced. Alpha/beta diversities and
genus-level taxa were analysed. Results: Mean ages at first sample procurement (MS/monoADS) = 18.0/13.8 years. Median
time (months) between first/second samples = 11.2 and second/third = 10.3.
Alpha/beta diversities did not differ between stool samples
(p > 0.09), while one genus –
Solobacterium did (p = 0.001). Conclusions: The gut microbiota composition in paediatric-onset MS and monoADS exhibited
stability, suggesting that single stool sample procurement is a reasonable
first approach.
Collapse
Affiliation(s)
- Geoffrey Liang
- Division of Neurology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada/The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada
| | - Feng Zhu
- Division of Neurology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada/The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada
| | - Ali I Mirza
- Division of Neurology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada/The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada
| | - Amit Bar-Or
- Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Charles N Bernstein
- Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences and University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, University of Manitoba, Winnipeg, MB, Canada
| | - Christine Bonner
- National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
| | - Jessica D Forbes
- Roy Romanow Provincial Laboratory, Regina, SK, Canada/Department of Pathology and Laboratory Medicine, University of Saskatchewan, Saskatoon, SK, Canada
| | - Morag Graham
- National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada/Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, MB, Canada
| | - Janace Hart
- Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - Natalie C Knox
- National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada/Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, MB, Canada
| | - Ruth Ann Marrie
- Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Manitoba, Canada
| | - Julia O'Mahony
- The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| | - Gary Van Domselaar
- National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada/Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, MB, Canada
| | - E Ann Yeh
- The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
| | - Yinshan Zhao
- Division of Neurology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada/The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada
| | - Brenda Banwell
- Division of Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Emmanuelle Waubant
- Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - Helen Tremlett
- Division of Neurology, Faculty of Medicine, The University of British Columbia, Vancouver, BC, Canada/The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, Canada
| | | |
Collapse
|
11
|
Mirza AI, Zhu F, Knox N, Forbes JD, Van Domselaar G, Bernstein CN, Graham M, Marrie RA, Hart J, Yeh EA, Arnold DL, Bar-Or A, O'Mahony J, Zhao Y, Hsiao W, Banwell B, Waubant E, Tremlett H. Metagenomic Analysis of the Pediatric-Onset Multiple Sclerosis Gut Microbiome. Neurology 2022; 98:e1050-e1063. [PMID: 34937787 PMCID: PMC8967388 DOI: 10.1212/wnl.0000000000013245] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 12/13/2021] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Little is known of the functional potential of the gut microbiome in pediatric-onset multiple sclerosis (MS). We performed metagenomic analyses using stool samples from individuals with pediatric-onset MS and unaffected controls. METHODS Persons ≤21 years old enrolled in the Canadian Pediatric Demyelinating Disease Network providing a stool sample were eligible. Twenty patients with MS (McDonald criteria) with symptom onset <18 years were matched to 20 controls by sex, age (±3 years), stool consistency, and race. Microbial taxonomy and functional potentials were estimated from stool sample-derived metagenomic reads and compared by disease status (MS vs controls) and disease-modifying drug (DMD) exposure using alpha diversity, relative abundance, and prevalence using Wilcoxon rank sum, ALDEx2, and Fisher exact tests, respectively. RESULTS Individuals with MS were aged 13.6 years (mean) at symptom onset and 8 were DMD-naive. Mean ages at stool sample were 16.1 and 15.4 years for MS and control participants, respectively; 80% were girls. Alpha diversity of enzymes and proteins did not differ by disease or DMD status (p > 0.20), but metabolic pathways, gene annotations, and microbial taxonomy did. Individuals with MS (vs controls) exhibited higher methanogenesis prevalence (odds ratio 10, p = 0.044) and Methanobrevibacter abundance (log2 fold change [LFC] 1.7, p = 0.0014), but lower homolactic fermentation abundance (LFC -0.48, p = 0.039). Differences by DMD status included lower phosphate butyryl transferase for DMD-naive vs exposed patients with MS (LFC -1.0, p = 0.033). DISCUSSION The gut microbiome's functional potential and taxonomy differed between individuals with pediatric-onset MS vs controls, including higher prevalence of a methane-producing pathway from Archaea and depletion of the lactate fermentation pathway. DMD exposure was associated with butyrate-producing enzyme enrichment. Together these findings indicate that the gut microbiome of individuals with MS may have a disturbed functional potential.
Collapse
Affiliation(s)
- Ali I Mirza
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Feng Zhu
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Natalie Knox
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Jessica D Forbes
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Gary Van Domselaar
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Charles N Bernstein
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Morag Graham
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Ruth Ann Marrie
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Janace Hart
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - E Ann Yeh
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Douglas L Arnold
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Amit Bar-Or
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Julia O'Mahony
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Yinshan Zhao
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - William Hsiao
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Brenda Banwell
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Emmanuelle Waubant
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA
| | - Helen Tremlett
- From the Department of Medicine (Neurology) (A.I.M., F.Z., Y.Z., H.T.), The University of British Columbia, Vancouver; National Microbiology Laboratory (N.K., G.V.D., M.G.), Public Health Agency of Canada; Department of Medical Microbiology and Infectious Diseases (N.K., G.V.D., M.G.), Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences (C.N.B., R.A.M.), and Inflammatory Bowel Disease Clinical and Research Centre (C.N.B.), University of Manitoba, Winnipeg; Roy Romanow Provincial Laboratory (J.D.F.), Regina; Department of Pathology and Laboratory Medicine (J.D.F.), College of Medicine, University of Saskatchewan, Saskatoon, Canada; Department of Neurology (J.H., E.W.), University of California San Francisco; Department of Pediatrics (Neurology) (E.A.Y., J.O.), The Hospital for Sick Children, Toronto; Department of Neurology and Neurosurgery (D.L.A.), Montreal Neurological Institute, McGill University, Montreal, Canada; Centre for Neuroinflammation and Experimental Therapeutics and Department of Neurology (A.B.-O.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Faculty of Health Sciences (W.H.), Simon Fraser University, Burnaby, Canada; and The Children's Hospital of Philadelphia (B.B.), PA.
| |
Collapse
|
12
|
Tremlett H, Zhu F, Arnold D, Bar-Or A, Bernstein CN, Bonner C, Forbes JD, Graham M, Hart J, Knox NC, Marrie RA, Mirza AI, O'Mahony J, Van Domselaar G, Yeh EA, Zhao Y, Banwell B, Waubant E. The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Ann Clin Transl Neurol 2021; 8:2252-2269. [PMID: 34889081 PMCID: PMC8670321 DOI: 10.1002/acn3.51476] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Accepted: 10/22/2021] [Indexed: 12/15/2022] Open
Abstract
Objective To examine the gut microbiota in individuals with and without pediatric‐onset multiple sclerosis (MS). Methods We compared stool‐derived microbiota of Canadian Pediatric Demyelinating Disease Network study participants ≤21 years old, with MS (disease‐modifying drug [DMD] exposed and naïve) or monophasic acquired demyelinating syndrome [monoADS] (symptom onset <18 years), and unaffected controls. All were ≥30 days without antibiotics or corticosteroids. V4 region 16S RNA gene‐derived amplicon sequence variants (Illumina MiSeq) were assessed using negative binomial regression and network analyses; rate ratios were age‐ and sex‐adjusted (aRR). Results Thirty‐two MS, 41 monoADS (symptom onset [mean] = 14.0 and 6.9 years) and 36 control participants were included; 75%/56%/58% were female, with mean ages at stool sample = 16.5/13.8/15.1 years, respectively. Nine MS cases (28%) were DMD‐naïve. Although microbiota diversity (alpha, beta) did not differ between participants (p > 0.1), taxa‐level and gut community networks did. MS (vs. monoADS) exhibited > fourfold higher relative abundance of the superphylum Patescibacteria (aRR = 4.2;95%CI:1.6–11.2, p = 0.004, Q = 0.01), and lower abundances of short‐chain fatty acid (SCFA)‐producing Lachnospiraceae (Anaerosporobacter) and Ruminococcaceae (p, Q < 0.05). DMD‐naïve MS cases were depleted for Clostridiales vadin‐BB60 (unnamed species) versus either DMD‐exposed, controls (p, Q < 0.01), or monoADS (p = 0.001, Q = 0.06) and exhibited altered community connectedness (p < 10−9 Kruskal–Wallis), with SCFA‐producing taxa underrepresented. Consistent taxa‐level findings from an independent US Network of Pediatric MS Centers case/control (n = 51/42) cohort included >eightfold higher abundance for Candidatus Stoquefichus and Tyzzerella (aRR = 8.8–12.8, p < 0.05) in MS cases and 72%–80% lower abundance of SCFA‐producing Ruminococcaceae‐NK4A214 (aRR = 0.38–0.2, p ≤ 0.01). Interpretation Gut microbiota community structure, function and connectivity, and not just individual taxa, are of likely importance in MS.
Collapse
Affiliation(s)
- Helen Tremlett
- Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, V6T 1Z3, Canada
| | - Feng Zhu
- Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, V6T 1Z3, Canada
| | - Douglas Arnold
- The Montreal Neurological Institute, McGill University, Montreal, Quebec, H3A 2B4, Canada
| | - Amit Bar-Or
- Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perleman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA
| | - Charles N Bernstein
- Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, University of Manitoba, Winnipeg, Manitoba, R3E 3P4, Canada
| | - Christine Bonner
- National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, R3E 3R2, Canada
| | - Jessica D Forbes
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5S 1A8, Canada
| | - Morag Graham
- National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, R3E 3R2, Canada.,Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Manitoba, R3E 0J9, Canada
| | - Janace Hart
- Department of Neurology, University of California San Francisco, San Francisco, California, 94158, USA
| | - Natalie C Knox
- National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, R3E 3R2, Canada.,Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Manitoba, R3E 0J9, Canada
| | - Ruth Ann Marrie
- Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Manitoba, R3A 1R9, Canada
| | - Ali I Mirza
- Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, V6T 1Z3, Canada
| | - Julia O'Mahony
- The Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
| | - Gary Van Domselaar
- National Microbiology Laboratory, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, R3E 3R2, Canada.,Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, Rady Faculty of Health Sciences, Winnipeg, Manitoba, R3E 0J9, Canada
| | - E Ann Yeh
- The Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
| | - Yinshan Zhao
- Medicine (Neurology), University of British Columbia and The Djavad Mowafaghian Centre for Brain Health, Vancouver, BC, V6T 1Z3, Canada
| | - Brenda Banwell
- Division of Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA
| | - Emmanuelle Waubant
- Department of Neurology, University of California San Francisco, San Francisco, California, 94158, USA
| | | |
Collapse
|
13
|
Graham M, Bird S, Howard Z, Dobson M, Palazzi K, Lucas CJ, Schneider J, Eagar K, Martin JH. NSW Cannabis Medicines Advisory Service preliminary survey results - Enquirer perceptions and patient outcomes. Intern Med J 2021; 52:228-237. [PMID: 34837455 PMCID: PMC9304266 DOI: 10.1111/imj.15635] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 11/04/2021] [Accepted: 11/23/2021] [Indexed: 11/28/2022]
Abstract
Background In 2018, an innovative, State government‐funded cannabis medicines drug information service was established for health professionals in New South Wales (NSW). The NSW Cannabis Medicines Advisory Service (CMAS) provides expert clinical guidance and support to medical practitioners considering prescribing a cannabis medicine to their patient(s). Aims This research examines quality assurance and patient outcomes related to enquirers' experience with NSW CMAS. Methods Data collection involved an online, anonymous survey with two components. Following a health professional enquiry, quality assurance data were collected about the enquirers' experience with NSW CMAS. The second survey focussed on patient outcomes and provides real‐world observational data about cannabis medicines safety and effectiveness across a wide range of indications. Results Data collection occurred between January 2020 and June 2021. Preliminary analyses were based on 68 quality assurance and 50 patient outcomes survey responses. General practitioners represented the highest proportion of survey responses (n = 33; 49%). The most common enquiry involved ‘patient‐specific advice’ (n = 50; 74%). Patient‐specific information provided by the service was mainly used for prescribing decision support (n = 45; 90%). Conclusions Preliminary findings highlight the impact of an innovative cannabis medicines drug information service in supporting health professional clinical practice in an area of rapid knowledge translation. Quality assurance data indicate that the service is perceived well by the majority of enquirers. Patient outcomes data across a wide range of indications suggest some effectiveness and a reasonable safety profile for prescribed cannabis medicines for most patients.
Collapse
Affiliation(s)
- M Graham
- NSW Cannabis Medicines Advisory Service, Newcastle, New South Wales, Australia.,Australian Centre for Cannabinoid Clinical and Research Excellence, Newcastle, New South Wales, Australia.,Centre for Drug Repurposing & Medicines Research, School of Medicine and Public Health, The University of Newcastle, New South Wales, Australia.,Hunter Medical Research Institute, Newcastle, New South Wales, Australia.,John Hunter Hospital, Hunter New England Local Health District, New Lambton, New South Wales, Australia
| | - S Bird
- Australian Health Services Research Institute, University of Wollongong, New South Wales, Australia
| | - Z Howard
- School of Psychological Science, University of Western Australia, Western Australia, Australia
| | - M Dobson
- John Hunter Hospital, Hunter New England Local Health District, New Lambton, New South Wales, Australia
| | - K Palazzi
- Hunter Medical Research Institute, Newcastle, New South Wales, Australia
| | - C J Lucas
- Australian Centre for Cannabinoid Clinical and Research Excellence, Newcastle, New South Wales, Australia.,Centre for Drug Repurposing & Medicines Research, School of Medicine and Public Health, The University of Newcastle, New South Wales, Australia.,Hunter Medical Research Institute, Newcastle, New South Wales, Australia.,John Hunter Hospital, Hunter New England Local Health District, New Lambton, New South Wales, Australia
| | - J Schneider
- Australian Centre for Cannabinoid Clinical and Research Excellence, Newcastle, New South Wales, Australia.,Centre for Drug Repurposing & Medicines Research, School of Medicine and Public Health, The University of Newcastle, New South Wales, Australia
| | - K Eagar
- Australian Health Services Research Institute, University of Wollongong, New South Wales, Australia
| | - J H Martin
- Australian Centre for Cannabinoid Clinical and Research Excellence, Newcastle, New South Wales, Australia.,Centre for Drug Repurposing & Medicines Research, School of Medicine and Public Health, The University of Newcastle, New South Wales, Australia.,Hunter Medical Research Institute, Newcastle, New South Wales, Australia
| |
Collapse
|
14
|
Kobo O, Khattak S, Lopez-Mattei J, Van Spall H, Graham M, Cheng R, Osman M, Sun L, Ullah W, Fischman D, Roguin A, Mohamed OM, Mamas MA. Trends in cardiovascular mortality of cancer patients in the US over two decades 1999–2019. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Cancer is the second most common cause of death globally after cardiovascular (CV) disease. The present study sought to compare the trends in CV mortality between patients with and without cancer in the US over two decades (1999 to 2019), stratified by sociodemographic factors such as age, sex and geographical location.
Methods
In this retrospective study, the number of deaths, crude- and age-adjusted mortality rates between January 1, 1999, and December 31, 2019, were obtained from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) data set
Results
We examined a total of 53,422,612 deaths between 1999 and 2019; of which 33.4% were defined as CV mortality and 25.6% had malignancy. During this period, among patients with cancer, the age-adjusted mortality rate dropped by 52%. (Vs, 38% in patients with no malignancy). CV mortality was highest in patients with gastrointestinal and prostate malignancy where CV mortality accounts together for over 40% of all CV mortality in patients with cancer in 1999 and 33.6% in 2019. The age-adjusted CV mortality rate (per 100,000 people) of patients with GI and prostate cancer nearly halved over twenty years from 2.7 to 1.0 and 2.5 to 1.0.
The CV age-adjusted mortality rate dropped more significantly among patients with gastrointestinal, breast, and prostate malignancy than among patients with hematological malignancy (59–63% vs. 41%. We observed that crude CV mortality rates amongst patients with cancer declined over the study period in all age groups but was more prominent among patients over 65 years old than those aged 55–64 and under 55 (51%-55% Vs. 41%, 25%, respectively).Similar reductions in mortality in men and women (54% and 53% reduction) were observed
During the study period the decline in cardiovascular mortality was more prominent in metro areas which led to lower age adjusted CV mortality in Metro compared to non-Metro areas (5.7–6.3 vs 7.2). The decline in age adjusted CV mortality in patients with cancer differed significantly in different states
Conclusions
In our temporal analysis we show a 50% decline in CV mortality in the US over two decades in both male and female patients with cancer, that has exceeded the reduction in CV mortality seen in the non-cancer population. The greatest reductions in CV mortality were observed in patients with GI, breast and prostate malignancies, those residing in metro areas and in patients aged 65 and over.
Funding Acknowledgement
Type of funding sources: None. CV death among cancer patients
Collapse
Affiliation(s)
- O Kobo
- Hillel Yaffe Medical Center, Hadera, Israel
| | - S Khattak
- Keele University, Stoke-on-Trent, United Kingdom
| | - J Lopez-Mattei
- University of Texas Health Science Center, Houston, United States of America
| | - H Van Spall
- Population Health Research Institute, Hamilton, Canada
| | - M Graham
- University of Alberta, Edmonton, Canada
| | - R Cheng
- University of Washington, Seattle, United States of America
| | - M Osman
- West Virginia Institute Heart and Vascular Institute, Morgantown, United States of America
| | - L Sun
- University of Ottawa Heart Institute, Ottawa, Canada
| | - W Ullah
- Thomas Jefferson University, Philadelphia, United States of America
| | - D Fischman
- Thomas Jefferson University, Philadelphia, United States of America
| | - A Roguin
- Hillel Yaffe Medical Center, Hadera, Israel
| | - O M Mohamed
- Keele University, Stoke-on-Trent, United Kingdom
| | - M A Mamas
- Keele University, Stoke-on-Trent, United Kingdom
| |
Collapse
|
15
|
Swan T, Ritmejerytė E, Sebayang B, Jones R, Devine G, Graham M, Zich FA, Staunton KM, Russell TL, Burkot TR. Sugar prevalence in Aedes albopictus differs by habitat, sex and time of day on Masig Island, Torres Strait, Australia. Parasit Vectors 2021; 14:520. [PMID: 34625096 PMCID: PMC8501651 DOI: 10.1186/s13071-021-05020-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 09/14/2021] [Indexed: 11/21/2022] Open
Abstract
Background Sugar feeding is a fundamental behaviour of many mosquito species. For Aedes albopictus, an important vector of dengue virus and chikungunya virus, little is known about its sugar-feeding behaviour, and no studies have been conducted on this in the southern hemisphere. This knowledge is pivotal for determining the potential of attractive targeted sugar baits (ATSBs) to control this important vector. Methods The prevalence of sugar was assessed in 1808 Ae. albopictus from Masig Island, Torres Strait, Australia collected between 13 and 25 March 2020. Fructose presence and content in field-collected Ae. albopictus were quantified using the cold anthrone assay. Results Significantly more male (35.8%) than female (28.4%) Ae. albopictus were sugar fed. There was a significant interaction between sex and time of day on the probability of capturing sugar-fed Ae. albopictus. For both sexes, fructose prevalence and content were higher in mosquitoes caught in the morning than in the afternoon. Female Ae. albopictus collected in the residential habitat were significantly more likely to be sugar fed than those collected in the woodland habitat. Conclusions These findings provide baseline information about the sugar-feeding patterns of Ae. albopictus and provide essential information to enable an assessment of the potential of ATSBs for vector suppression and control on Masig Island, with relevance to other locations where this species occurs. Graphical abstract ![]()
Supplementary Information The online version contains supplementary material available at 10.1186/s13071-021-05020-w.
Collapse
Affiliation(s)
- T Swan
- College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Australia. .,Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia.
| | - E Ritmejerytė
- Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia
| | - B Sebayang
- College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Australia.,Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia
| | - R Jones
- Division of Tropical Health and Medicine, James Cook University, Townsville, Australia
| | - G Devine
- Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - M Graham
- Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - F A Zich
- Australian Tropical Herbarium, James Cook University, Cairns, Australia.,National Research Collections Australia, Commonwealth Industrial and Scientific Research Organisation (CSIRO), Canberra, Australia
| | - K M Staunton
- College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Australia.,Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia
| | - T L Russell
- College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Australia.,Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia
| | - T R Burkot
- College of Public Health, Medical and Veterinary Sciences, James Cook University, Cairns, Australia.,Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, Australia
| |
Collapse
|
16
|
Bond KA, Williams E, Nicholson S, Lim S, Johnson D, Cox B, Putland M, Gardiner E, Tippett E, Graham M, Mordant F, Catton M, Lewin SR, Subbarao K, Howden BP, Williamson DA. Longitudinal evaluation of laboratory-based serological assays for SARS-CoV-2 antibody detection. Pathology 2021; 53:773-779. [PMID: 34412859 PMCID: PMC8289701 DOI: 10.1016/j.pathol.2021.05.093] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 05/02/2021] [Accepted: 05/17/2021] [Indexed: 01/03/2023]
Abstract
Serological assays for SARS-CoV-2 infection are now widely available for use in diagnostic laboratories. Limited data are available on the performance characteristics in different settings, and at time periods remote from the initial infection. Validation of the Abbott (Architect SARS-CoV-2 IgG), DiaSorin (Liaison SARS-CoV-2 S1/S2 IgG) and Roche (Cobas Elecsys Anti-SARS-CoV-2) assays was undertaken utilising 217 serum samples from 131 participants up to 7 months following COVID-19 infection. The Abbott and DiaSorin assays were implemented into routine laboratory workflow, with outcomes reported for 2764 clinical specimens. Sensitivity and specificity were concordant with the range reported by the manufacturers for all assays. Sensitivity across the convalescent period was highest for the Roche at 95.2-100% (95% CI 81.0-100%), then the DiaSorin at 88.1-100% (95% CI 76.0-100%), followed by the Abbott 68.2-100% (95% CI 53.4-100%). Sensitivity of the Abbott assay fell from approximately 5 months; on this assay paired serum samples for 45 participants showed a significant drop in the signal-to-cut-off ratio and 10 sero-reversion events. When used in clinical practice, all samples testing positive by both DiaSorin and Abbott assays were confirmed as true positive results. In this low prevalence setting, despite high laboratory specificity, the positive predictive value of a single positive assay was low. Comprehensive validation of serological assays is necessary to determine the optimal assay for each diagnostic setting. In this low prevalence setting we found implementation of two assays with different antibody targets maximised sensitivity and specificity, with confirmatory testing necessary for any sample which was positive in only one assay.
Collapse
Affiliation(s)
- K A Bond
- Department of Microbiology, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia.
| | - E Williams
- Department of Microbiology, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
| | - S Nicholson
- Victorian Infectious Diseases Reference Laboratory at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
| | - S Lim
- Department of General Medicine and Infectious Diseases, Royal Melbourne Hospital, Melbourne, Vic, Australia; Department of General Medicine, The University of Melbourne, Vic, Australia
| | - D Johnson
- Department of General Medicine and Infectious Diseases, Royal Melbourne Hospital, Melbourne, Vic, Australia; Department of General Medicine, The University of Melbourne, Vic, Australia
| | - B Cox
- Department of Microbiology, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; Department of General Medicine and Infectious Diseases, Royal Melbourne Hospital, Melbourne, Vic, Australia
| | - M Putland
- Department of Emergency Medicine, Royal Melbourne Hospital, Melbourne, Vic, Australia
| | - E Gardiner
- Department of Emergency Medicine, Royal Melbourne Hospital, Melbourne, Vic, Australia
| | - E Tippett
- Department of Microbiology, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; Department of General Medicine and Infectious Diseases, Royal Melbourne Hospital, Melbourne, Vic, Australia
| | - M Graham
- Department of Microbiology and Infectious Diseases, Monash Health, Vic, Australia; The Peter Doherty Institute for Infection and Immunity, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Vic, Australia
| | - F Mordant
- WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
| | - M Catton
- Victorian Infectious Diseases Reference Laboratory at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
| | - S R Lewin
- The Peter Doherty Institute for Infection and Immunity, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Vic, Australia; Department of Infectious Diseases, Alfred Hospital and Monash University, Melbourne, Vic, Australia
| | - K Subbarao
- Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
| | - B P Howden
- Department of Microbiology, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; The Peter Doherty Institute for Infection and Immunity, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Vic, Australia; Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
| | - D A Williamson
- Department of Microbiology, Royal Melbourne Hospital at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia; The Peter Doherty Institute for Infection and Immunity, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Vic, Australia; Microbiological Diagnostic Unit Public Health Laboratory, Department of Microbiology and Immunology, The University of Melbourne at The Peter Doherty Institute for Infection and Immunity, Melbourne, Vic, Australia
| |
Collapse
|
17
|
Abi B, Acciarri R, Acero MA, Adamov G, Adams D, Adinolfi M, Ahmad Z, Ahmed J, Alion T, Monsalve SA, Alt C, Anderson J, Andreopoulos C, Andrews MP, Andrianala F, Andringa S, Ankowski A, Antonova M, Antusch S, Aranda-Fernandez A, Ariga A, Arnold LO, Arroyave MA, Asaadi J, Aurisano A, Aushev V, Autiero D, Azfar F, Back H, Back JJ, Backhouse C, Baesso P, Bagby L, Bajou R, Balasubramanian S, Baldi P, Bambah B, Barao F, Barenboim G, Barker GJ, Barkhouse W, Barnes C, Barr G, Monarca JB, Barros N, Barrow JL, Bashyal A, Basque V, Bay F, Alba JLB, Beacom JF, Bechetoille E, Behera B, Bellantoni L, Bellettini G, Bellini V, Beltramello O, Belver D, Benekos N, Neves FB, Berger J, Berkman S, Bernardini P, Berner RM, Berns H, Bertolucci S, Betancourt M, Bezawada Y, Bhattacharjee M, Bhuyan B, Biagi S, Bian J, Biassoni M, Biery K, Bilki B, Bishai M, Bitadze A, Blake A, Siffert BB, Blaszczyk FDM, Blazey GC, Blucher E, Boissevain J, Bolognesi S, Bolton T, Bonesini M, Bongrand M, Bonini F, Booth A, Booth C, Bordoni S, Borkum A, Boschi T, Bostan N, Bour P, Boyd SB, Boyden D, Bracinik J, Braga D, Brailsford D, Brandt A, Bremer J, Brew C, Brianne E, Brice SJ, Brizzolari C, Bromberg C, Brooijmans G, Brooke J, Bross A, Brunetti G, Buchanan N, Budd H, Caiulo D, Calafiura P, Calcutt J, Calin M, Calvez S, Calvo E, Camilleri L, Caminata A, Campanelli M, Caratelli D, Carini G, Carlus B, Carniti P, Terrazas IC, Carranza H, Castillo A, Castromonte C, Cattadori C, Cavalier F, Cavanna F, Centro S, Cerati G, Cervelli A, Villanueva AC, Chalifour M, Chang C, Chardonnet E, Chatterjee A, Chattopadhyay S, Chaves J, Chen H, Chen M, Chen Y, Cherdack D, Chi C, Childress S, Chiriacescu A, Cho K, Choubey S, Christensen A, Christian D, Christodoulou G, Church E, Clarke P, Coan TE, Cocco AG, Coelho JAB, Conley E, Conrad JM, Convery M, Corwin L, Cotte P, Cremaldi L, Cremonesi L, Crespo-Anadón JI, Cristaldo E, Cross R, Cuesta C, Cui Y, Cussans D, Dabrowski M, da Motta H, Peres LDS, David C, David Q, Davies GS, Davini S, Dawson J, De K, De Almeida RM, Debbins P, De Bonis I, Decowski MP, de Gouvêa A, De Holanda PC, De Icaza Astiz IL, Deisting A, De Jong P, Delbart A, Delepine D, Delgado M, Dell’Acqua A, De Lurgio P, de Mello Neto JRT, DeMuth DM, Dennis S, Densham C, Deptuch G, De Roeck A, De Romeri V, De Vries JJ, Dharmapalan R, Dias M, Diaz F, Díaz JS, Di Domizio S, Di Giulio L, Ding P, Di Noto L, Distefano C, Diurba R, Diwan M, Djurcic Z, Dokania N, Dolinski MJ, Domine L, Douglas D, Drielsma F, Duchesneau D, Duffy K, Dunne P, Durkin T, Duyang H, Dvornikov O, Dwyer DA, Dyshkant AS, Eads M, Edmunds D, Eisch J, Emery S, Ereditato A, Escobar CO, Sanchez LE, Evans JJ, Ewart E, Ezeribe AC, Fahey K, Falcone A, Farnese C, Farzan Y, Felix J, Fernandez-Martinez E, Fernandez Menendez P, Ferraro F, Fields L, Filkins A, Filthaut F, Fitzpatrick RS, Flanagan W, Fleming B, Flight R, Fowler J, Fox W, Franc J, Francis K, Franco D, Freeman J, Freestone J, Fried J, Friedland A, Fuess S, Furic I, Furmanski AP, Gago A, Gallagher H, Gallego-Ros A, Gallice N, Galymov V, Gamberini E, Gamble T, Gandhi R, Gandrajula R, Gao S, Garcia-Gamez D, García-Peris MÁ, Gardiner S, Gastler D, Ge G, Gelli B, Gendotti A, Gent S, Ghorbani-Moghaddam Z, Gibin D, Gil-Botella I, Girerd C, Giri AK, Gnani D, Gogota O, Gold M, Gollapinni S, Gollwitzer K, Gomes RA, Bermeo LVG, Fajardo LSG, Gonnella F, Gonzalez-Cuevas JA, Goodman MC, Goodwin O, Goswami S, Gotti C, Goudzovski E, Grace C, Graham M, Gramellini E, Gran R, Granados E, Grant A, Grant C, Gratieri D, Green P, Green S, Greenler L, Greenwood M, Greer J, Griffith WC, Groh M, Grudzinski J, Grzelak K, Gu W, Guarino V, Guenette R, Guglielmi A, Guo B, Guthikonda KK, Gutierrez R, Guzowski P, Guzzo MM, Gwon S, Habig A, Hackenburg A, Hadavand H, Haenni R, Hahn A, Haigh J, Haiston J, Hamernik T, Hamilton P, Han J, Harder K, Harris DA, Hartnell J, Hasegawa T, Hatcher R, Hazen E, Heavey A, Heeger KM, Heise J, Hennessy K, Henry S, Morquecho MAH, Herner K, Hertel L, Hesam AS, Hewes J, Higuera A, Hill T, Hillier SJ, Himmel A, Hoff J, Hohl C, Holin A, Hoppe E, Horton-Smith GA, Hostert M, Hourlier A, Howard B, Howell R, Huang J, Huang J, Hugon J, Iles G, Ilic N, Iliescu AM, Illingworth R, Ioannisian A, Itay R, Izmaylov A, James E, Jargowsky B, Jediny F, Jesùs-Valls C, Ji X, Jiang L, Jiménez S, Jipa A, Joglekar A, Johnson C, Johnson R, Jones B, Jones S, Jung CK, Junk T, Jwa Y, Kabirnezhad M, Kaboth A, Kadenko I, Kamiya F, Karagiorgi G, Karcher A, Karolak M, Karyotakis Y, Kasai S, Kasetti SP, Kashur L, Kazaryan N, Kearns E, Keener P, Kelly KJ, Kemp E, Ketchum W, Kettell SH, Khabibullin M, Khotjantsev A, Khvedelidze A, Kim D, King B, Kirby B, Kirby M, Klein J, Koehler K, Koerner LW, Kohn S, Koller PP, Kordosky M, Kosc T, Kose U, Kostelecký VA, Kothekar K, Krennrich F, Kreslo I, Kudenko Y, Kudryavtsev VA, Kulagin S, Kumar J, Kumar R, Kuruppu C, Kus V, Kutter T, Lambert A, Lande K, Lane CE, Lang K, Langford T, Lasorak P, Last D, Lastoria C, Laundrie A, Lawrence A, Lazanu I, LaZur R, Le T, Learned J, LeBrun P, Miotto GL, Lehnert R, de Oliveira MAL, Leitner M, Leyton M, Li L, Li S, Li SW, Li T, Li Y, Liao H, Lin CS, Lin S, Lister A, Littlejohn BR, Liu J, Lockwitz S, Loew T, Lokajicek M, Lomidze I, Long K, Loo K, Lorca D, Lord T, LoSecco JM, Louis WC, Luk KB, Luo X, Lurkin N, Lux T, Luzio VP, MacFarland D, Machado AA, Machado P, Macias CT, Macier JR, Maddalena A, Madigan P, Magill S, Mahn K, Maio A, Maloney JA, Mandrioli G, Maneira J, Manenti L, Manly S, Mann A, Manolopoulos K, Plata MM, Marchionni A, Marciano W, Marfatia D, Mariani C, Maricic J, Marinho F, Marino AD, Marshak M, Marshall C, Marshall J, Marteau J, Martin-Albo J, Martinez N, Caicedo DAM, Martynenko S, Mason K, Mastbaum A, Masud M, Matsuno S, Matthews J, Mauger C, Mauri N, Mavrokoridis K, Mazza R, Mazzacane A, Mazzucato E, McCluskey E, McConkey N, McFarland KS, McGrew C, McNab A, Mefodiev A, Mehta P, Melas P, Mellinato M, Mena O, Menary S, Mendez H, Menegolli A, Meng G, Messier MD, Metcalf W, Mewes M, Meyer H, Miao T, Michna G, Miedema T, Migenda J, Milincic R, Miller W, Mills J, Milne C, Mineev O, Miranda OG, Miryala S, Mishra CS, Mishra SR, Mislivec A, Mladenov D, Mocioiu I, Moffat K, Moggi N, Mohanta R, Mohayai TA, Mokhov N, Molina J, Bueno LM, Montanari A, Montanari C, Montanari D, Zetina LMM, Moon J, Mooney M, Moor A, Moreno D, Morgan B, Morris C, Mossey C, Motuk E, Moura CA, Mousseau J, Mu W, Mualem L, Mueller J, Muether M, Mufson S, Muheim F, Muir A, Mulhearn M, Muramatsu H, Murphy S, Musser J, Nachtman J, Nagu S, Nalbandyan M, Nandakumar R, Naples D, Narita S, Navas-Nicolás D, Nayak N, Nebot-Guinot M, Necib L, Negishi K, Nelson JK, Nesbit J, Nessi M, Newbold D, Newcomer M, Newhart D, Nichol R, Niner E, Nishimura K, Norman A, Norrick A, Northrop R, Novella P, Nowak JA, Oberling M, Del Campo AO, Olivier A, Onel Y, Onishchuk Y, Ott J, Pagani L, Pakvasa S, Palamara O, Palestini S, Paley JM, Pallavicini M, Palomares C, Pantic E, Paolone V, Papadimitriou V, Papaleo R, Papanestis A, Paramesvaran S, Park JC, Parke S, Parsa Z, Parvu M, Pascoli S, Pasqualini L, Pasternak J, Pater J, Patrick C, Patrizii L, Patterson RB, Patton SJ, Patzak T, Paudel A, Paulos B, Paulucci L, Pavlovic Z, Pawloski G, Payne D, Pec V, Peeters SJM, Penichot Y, Pennacchio E, Penzo A, Peres OLG, Perry J, Pershey D, Pessina G, Petrillo G, Petta C, Petti R, Piastra F, Pickering L, Pietropaolo F, Pillow J, Pinzino J, Plunkett R, Poling R, Pons X, Poonthottathil N, Pordes S, Potekhin M, Potenza R, Potukuchi BVKS, Pozimski J, Pozzato M, Prakash S, Prakash T, Prince S, Prior G, Pugnere D, Qi K, Qian X, Raaf JL, Raboanary R, Radeka V, Rademacker J, Radics B, Rafique A, Raguzin E, Rai M, Rajaoalisoa M, Rakhno I, Rakotondramanana HT, Rakotondravohitra L, Ramachers YA, Rameika R, Delgado MAR, Ramson B, Rappoldi A, Raselli G, Ratoff P, Ravat S, Razafinime H, Real JS, Rebel B, Redondo D, Reggiani-Guzzo M, Rehak T, Reichenbacher J, Reitzner SD, Renshaw A, Rescia S, Resnati F, Reynolds A, Riccobene G, Rice LCJ, Rielage K, Rigaut Y, Rivera D, Rochester L, Roda M, Rodrigues P, Alonso MJR, Rondon JR, Roeth AJ, Rogers H, Rosauro-Alcaraz S, Rossella M, Rout J, Roy S, Rubbia A, Rubbia C, Russell B, Russell J, Ruterbories D, Saakyan R, Sacerdoti S, Safford T, Sahu N, Sala P, Samios N, Sanchez MC, Sanders DA, Sankey D, Santana S, Santos-Maldonado M, Saoulidou N, Sapienza P, Sarasty C, Sarcevic I, Savage G, Savinov V, Scaramelli A, Scarff A, Scarpelli A, Schaffer T, Schellman H, Schlabach P, Schmitz D, Scholberg K, Schukraft A, Segreto E, Sensenig J, Seong I, Sergi A, Sergiampietri F, Sgalaberna D, Shaevitz MH, Shafaq S, Shamma M, Sharma HR, Sharma R, Shaw T, Shepherd-Themistocleous C, Shin S, Shooltz D, Shrock R, Simard L, Simos N, Sinclair J, Sinev G, Singh J, Singh J, Singh V, Sipos R, Sippach FW, Sirri G, Sitraka A, Siyeon K, Smargianaki D, Smith A, Smith A, Smith E, Smith P, Smolik J, Smy M, Snopok P, Nunes MS, Sobel H, Soderberg M, Salinas CJS, Söldner-Rembold S, Solomey N, Solovov V, Sondheim WE, Sorel M, Soto-Oton J, Sousa A, Soustruznik K, Spagliardi F, Spanu M, Spitz J, Spooner NJC, Spurgeon K, Staley R, Stancari M, Stanco L, Steiner HM, Stewart J, Stillwell B, Stock J, Stocker F, Stocks D, Stokes T, Strait M, Strauss T, Striganov S, Stuart A, Summers D, Surdo A, Susic V, Suter L, Sutera CM, Svoboda R, Szczerbinska B, Szelc AM, Talaga R, Tanaka HA, Oregui BT, Tapper A, Tariq S, Tatar E, Tayloe R, Teklu AM, Tenti M, Terao K, Ternes CA, Terranova F, Testera G, Thea A, Thompson JL, Thorn C, Timm SC, Todd J, Tonazzo A, Torti M, Tortola M, Tortorici F, Totani D, Toups M, Touramanis C, Trevor J, Trzaska WH, Tsai YT, Tsamalaidze Z, Tsang KV, Tsverava N, Tufanli S, Tull C, Tyley E, Tzanov M, Uchida MA, Urheim J, Usher T, Vagins MR, Vahle P, Valdiviesso GA, Valencia E, Vallari Z, Valle JWF, Vallecorsa S, Berg RV, de Water RGV, Forero DV, Varanini F, Vargas D, Varner G, Vasel J, Vasseur G, Vaziri K, Ventura S, Verdugo A, Vergani S, Vermeulen MA, Verzocchi M, de Souza HV, Vignoli C, Vilela C, Viren B, Vrba T, Wachala T, Waldron AV, Wallbank M, Wang H, Wang J, Wang Y, Wang Y, Warburton K, Warner D, Wascko M, Waters D, Watson A, Weatherly P, Weber A, Weber M, Wei H, Weinstein A, Wenman D, Wetstein M, While MR, White A, Whitehead LH, Whittington D, Wilking MJ, Wilkinson C, Williams Z, Wilson F, Wilson RJ, Wolcott J, Wongjirad T, Wood K, Wood L, Worcester E, Worcester M, Wret C, Wu W, Wu W, Xiao Y, Yang G, Yang T, Yershov N, Yonehara K, Young T, Yu B, Yu J, Zaki R, Zalesak J, Zambelli L, Zamorano B, Zani A, Zazueta L, Zeller GP, Zennamo J, Zeug K, Zhang C, Zhao M, Zhao Y, Zhivun E, Zhu G, Zimmerman ED, Zito M, Zucchelli S, Zuklin J, Zutshi V, Zwaska R. Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment: DUNE Collaboration. Eur Phys J C Part Fields 2021; 81:322. [PMID: 34720713 PMCID: PMC8550327 DOI: 10.1140/epjc/s10052-021-09007-w] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Accepted: 02/23/2021] [Indexed: 06/13/2023]
Abstract
The Deep Underground Neutrino Experiment (DUNE) will be a powerful tool for a variety of physics topics. The high-intensity proton beams provide a large neutrino flux, sampled by a near detector system consisting of a combination of capable precision detectors, and by the massive far detector system located deep underground. This configuration sets up DUNE as a machine for discovery, as it enables opportunities not only to perform precision neutrino measurements that may uncover deviations from the present three-flavor mixing paradigm, but also to discover new particles and unveil new interactions and symmetries beyond those predicted in the Standard Model (SM). Of the many potential beyond the Standard Model (BSM) topics DUNE will probe, this paper presents a selection of studies quantifying DUNE's sensitivities to sterile neutrino mixing, heavy neutral leptons, non-standard interactions, CPT symmetry violation, Lorentz invariance violation, neutrino trident production, dark matter from both beam induced and cosmogenic sources, baryon number violation, and other new physics topics that complement those at high-energy colliders and significantly extend the present reach.
Collapse
Grants
- MR/T019530/1 Medical Research Council
- MR/T041323/1 Medical Research Council
- MSMT, Czech Republic
- NRF, South Korea
- Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- SERI, Switzerland
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- U.S. Department of Energy
- CERN
- Türkiye Bilimsel ve Teknolojik Arastirma Kurumu
- The Royal Society, United Kingdom
- Canada Foundation for Innovation
- U.S. NSF
- FCT, Portugal
- CEA, France
- CNRS/IN2P3, France
- European Regional Development Fund
- Science and Technology Facilities Council
- H2020-EU, European Union
- IPP, Canada
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- CAM, Spain
- MSCA, European Union
- Instituto Nazionale di Fisica Nucleare
- Fundacção de Amparo à Pesquisa do Estado de Goiás
- Ministerio de Ciencia e Innovación
- Fundacion “La Caixa” Spain
Collapse
Affiliation(s)
- B. Abi
- University of Oxford, Oxford, OX1 3RH UK
| | - R. Acciarri
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. A. Acero
- Universidad del Atlántico, Barranquilla, Atlántico Colombia
| | - G. Adamov
- Georgian Technical University, Tbilisi, Georgia
| | - D. Adams
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - Z. Ahmad
- Variable Energy Cyclotron Centre, Kolkata, West Bengal 700 064 India
| | - J. Ahmed
- University of Warwick, Coventry, CV4 7AL UK
| | - T. Alion
- University of Sussex, Brighton, BN1 9RH UK
| | - S. Alonso Monsalve
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - C. Alt
- ETH Zurich, Zurich, Switzerland
| | - J. Anderson
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - C. Andreopoulos
- University of Liverpool, Liverpool, L69 7ZE UK
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - M. P. Andrews
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - F. Andrianala
- University of Antananarivo, 101 Antananarivo, Madagascar
| | - S. Andringa
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003, Lisbon and, 3004-516 Coimbra, Portugal
| | - A. Ankowski
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - M. Antonova
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - S. Antusch
- University of Basel, 4056 Basel, Switzerland
| | | | - A. Ariga
- University of Bern, 3012 Bern, Switzerland
| | | | | | - J. Asaadi
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - A. Aurisano
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - V. Aushev
- Kyiv National University, Kiev, 01601 Ukraine
| | - D. Autiero
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - F. Azfar
- University of Oxford, Oxford, OX1 3RH UK
| | - H. Back
- Pacific Northwest National Laboratory, Richland, WA 99352 USA
| | - J. J. Back
- University of Warwick, Coventry, CV4 7AL UK
| | | | - P. Baesso
- University of Bristol, Bristol, BS8 1TL UK
| | - L. Bagby
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Bajou
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | | | - P. Baldi
- University of California Irvine, Irvine, CA 92697 USA
| | - B. Bambah
- University of Hyderabad, Gachibowli, Hyderabad, 500 046 India
| | - F. Barao
- Instituto Superior Técnico-IST, Universidade de Lisboa, Lisbon, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003, Lisbon and, 3004-516 Coimbra, Portugal
| | - G. Barenboim
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | | | - W. Barkhouse
- University of North Dakota, Grand Forks, ND 58202-8357 USA
| | - C. Barnes
- University of Michigan, Ann Arbor, MI 48109 USA
| | - G. Barr
- University of Oxford, Oxford, OX1 3RH UK
| | | | - N. Barros
- Faculdade de Ciências da Universidade de Lisboa-FCUL, 1749-016 Lisbon, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003, Lisbon and, 3004-516 Coimbra, Portugal
| | - J. L. Barrow
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- University of Tennessee at Knoxville, Knoxville, TN 37996 USA
| | - A. Bashyal
- Oregon State University, Corvallis, OR 97331 USA
| | - V. Basque
- University of Manchester, Manchester, M13 9PL UK
| | - F. Bay
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
| | | | | | - E. Bechetoille
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - B. Behera
- Colorado State University, Fort Collins, CO 80523 USA
| | - L. Bellantoni
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - V. Bellini
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - O. Beltramello
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - D. Belver
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - N. Benekos
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - F. Bento Neves
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003, Lisbon and, 3004-516 Coimbra, Portugal
| | - J. Berger
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - S. Berkman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - P. Bernardini
- Istituto Nazionale di Fisica Nucleare Sezione di Lecce, 73100 Lecce, Italy
- Università del Salento, 73100 Lecce, Italy
| | | | - H. Berns
- University of California Davis, Davis, CA 95616 USA
| | - S. Bertolucci
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - M. Betancourt
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - Y. Bezawada
- University of California Davis, Davis, CA 95616 USA
| | - M. Bhattacharjee
- Indian Institute of Technology Guwahati, Guwahati, 781 039 India
| | - B. Bhuyan
- Indian Institute of Technology Guwahati, Guwahati, 781 039 India
| | - S. Biagi
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - J. Bian
- University of California Irvine, Irvine, CA 92697 USA
| | - M. Biassoni
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - K. Biery
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - B. Bilki
- Beykent University, Istanbul, Turkey
- University of Iowa, Iowa City, IA 52242 USA
| | - M. Bishai
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Bitadze
- University of Manchester, Manchester, M13 9PL UK
| | - A. Blake
- Lancaster University, Lancaster, LA1 4YB UK
| | - B. Blanco Siffert
- Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-901 Brazil
| | | | - G. C. Blazey
- Northern Illinois University, DeKalb, IL 60115 USA
| | - E. Blucher
- University of Chicago, Chicago, IL 60637 USA
| | - J. Boissevain
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - S. Bolognesi
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | - T. Bolton
- Kansas State University, Manhattan, KS 66506 USA
| | - M. Bonesini
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - M. Bongrand
- Laboratoire de l’Accélérateur Linéaire, 91440 Orsay, France
| | - F. Bonini
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Booth
- University of Sussex, Brighton, BN1 9RH UK
| | - C. Booth
- University of Sheffield, Sheffield, S3 7RH UK
| | - S. Bordoni
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - A. Borkum
- University of Sussex, Brighton, BN1 9RH UK
| | - T. Boschi
- Durham University, Durham, DH1 3LE UK
| | - N. Bostan
- University of Iowa, Iowa City, IA 52242 USA
| | - P. Bour
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - S. B. Boyd
- University of Warwick, Coventry, CV4 7AL UK
| | - D. Boyden
- Northern Illinois University, DeKalb, IL 60115 USA
| | - J. Bracinik
- University of Birmingham, Birmingham, B15 2TT UK
| | - D. Braga
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - A. Brandt
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - J. Bremer
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - C. Brew
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - E. Brianne
- University of Manchester, Manchester, M13 9PL UK
| | - S. J. Brice
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - C. Brizzolari
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - C. Bromberg
- Michigan State University, East Lansing, MI 48824 USA
| | | | - J. Brooke
- University of Bristol, Bristol, BS8 1TL UK
| | - A. Bross
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Brunetti
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - N. Buchanan
- Colorado State University, Fort Collins, CO 80523 USA
| | - H. Budd
- University of Rochester, Rochester, NY 14627 USA
| | - D. Caiulo
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - P. Calafiura
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - J. Calcutt
- Michigan State University, East Lansing, MI 48824 USA
| | - M. Calin
- University of Bucharest, Bucharest, Romania
| | - S. Calvez
- Colorado State University, Fort Collins, CO 80523 USA
| | - E. Calvo
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | | | - A. Caminata
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | | | - D. Caratelli
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Carini
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - B. Carlus
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - P. Carniti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | | | - H. Carranza
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - A. Castillo
- Universidad Sergio Arboleda, Bogotá, 11022 Colombia
| | | | - C. Cattadori
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - F. Cavalier
- Laboratoire de l’Accélérateur Linéaire, 91440 Orsay, France
| | - F. Cavanna
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Centro
- Universtà degli Studi di Padova, 35131 Padua, Italy
| | - G. Cerati
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Cervelli
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | | | - M. Chalifour
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - C. Chang
- University of California Riverside, Riverside, CA 92521 USA
| | - E. Chardonnet
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | | | - S. Chattopadhyay
- Variable Energy Cyclotron Centre, Kolkata, West Bengal 700 064 India
| | - J. Chaves
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - H. Chen
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Chen
- University of California Irvine, Irvine, CA 92697 USA
| | - Y. Chen
- University of Bern, 3012 Bern, Switzerland
| | - D. Cherdack
- University of Houston, Houston, TX 77204 USA
| | - C. Chi
- Columbia University, New York, NY 10027 USA
| | - S. Childress
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - K. Cho
- Korea Institute of Science and Technology Information, Daejeon, 34141 South Korea
| | - S. Choubey
- Harish-Chandra Research Institute, Jhunsi, Allahabad, 211 019 India
| | | | - D. Christian
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Christodoulou
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - E. Church
- Pacific Northwest National Laboratory, Richland, WA 99352 USA
| | - P. Clarke
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | - T. E. Coan
- Southern Methodist University, Dallas, TX 75275 USA
| | - A. G. Cocco
- Istituto Nazionale di Fisica Nucleare Sezione di Napoli, 80126 Naples, Italy
| | | | - E. Conley
- Duke University, Durham, NC 27708 USA
| | - J. M. Conrad
- Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | - M. Convery
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - L. Corwin
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - P. Cotte
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | - L. Cremaldi
- University of Mississippi, University, MS 38677 USA
| | | | - J. I. Crespo-Anadón
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - E. Cristaldo
- Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | - R. Cross
- Lancaster University, Lancaster, LA1 4YB UK
| | - C. Cuesta
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - Y. Cui
- University of California Riverside, Riverside, CA 92521 USA
| | - D. Cussans
- University of Bristol, Bristol, BS8 1TL UK
| | - M. Dabrowski
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - H. da Motta
- Centro Brasileiro de Pesquisas Físicas, Rio de Janeiro, RJ 22290-180 Brazil
| | - L. Da Silva Peres
- Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-901 Brazil
| | - C. David
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- York University, Toronto, M3J 1P3 Canada
| | - Q. David
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - G. S. Davies
- University of Mississippi, University, MS 38677 USA
| | - S. Davini
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - J. Dawson
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - K. De
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - R. M. De Almeida
- Fluminense Federal University, 9 Icaraí, Niterói, RJ 24220-900 Brazil
| | - P. Debbins
- University of Iowa, Iowa City, IA 52242 USA
| | - I. De Bonis
- Laboratoire d’Annecy-le-Vieux de Physique des Particules, CNRS/IN2P3 and Université Savoie Mont Blanc, 74941 Annecy-le-Vieux, France
| | - M. P. Decowski
- University of Amsterdam, 1098 XG Amsterdam, The Netherlands
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
| | | | - P. C. De Holanda
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | | | | | - P. De Jong
- University of Amsterdam, 1098 XG Amsterdam, The Netherlands
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
| | - A. Delbart
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | - D. Delepine
- Universidad de Guanajuato, C.P. 37000 Guanajuato, Mexico
| | - M. Delgado
- Universidad Antonio Nariño, Bogotá, Colombia
| | - A. Dell’Acqua
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - P. De Lurgio
- Argonne National Laboratory, Argonne, IL 60439 USA
| | | | - D. M. DeMuth
- Valley City State University, Valley City, ND 58072 USA
| | - S. Dennis
- University of Cambridge, Cambridge, CB3 0HE UK
| | - C. Densham
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - G. Deptuch
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. De Roeck
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - V. De Romeri
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | | | | | - M. Dias
- Universidade Federal de São Paulo, São Paulo, 09913-030 Brazil
| | - F. Diaz
- Pontificia Universidad Católica del Perú, Lima, Peru
| | - J. S. Díaz
- Indiana University, Bloomington, IN 47405 USA
| | - S. Di Domizio
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - L. Di Giulio
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - P. Ding
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Di Noto
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - C. Distefano
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - R. Diurba
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - M. Diwan
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - Z. Djurcic
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - N. Dokania
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | | | - L. Domine
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - D. Douglas
- Michigan State University, East Lansing, MI 48824 USA
| | - F. Drielsma
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - D. Duchesneau
- Laboratoire d’Annecy-le-Vieux de Physique des Particules, CNRS/IN2P3 and Université Savoie Mont Blanc, 74941 Annecy-le-Vieux, France
| | - K. Duffy
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - P. Dunne
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - T. Durkin
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - H. Duyang
- University of South Carolina, Columbia, SC 29208 USA
| | | | - D. A. Dwyer
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | | | - M. Eads
- Northern Illinois University, DeKalb, IL 60115 USA
| | - D. Edmunds
- Michigan State University, East Lansing, MI 48824 USA
| | - J. Eisch
- Iowa State University, Ames, IA 50011 USA
| | - S. Emery
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | | | - C. O. Escobar
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - J. J. Evans
- University of Manchester, Manchester, M13 9PL UK
| | - E. Ewart
- Indiana University, Bloomington, IN 47405 USA
| | | | - K. Fahey
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Falcone
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - C. Farnese
- Universtà degli Studi di Padova, 35131 Padua, Italy
| | - Y. Farzan
- Institute for Research in Fundamental Sciences, Tehran, Iran
| | - J. Felix
- Universidad de Guanajuato, C.P. 37000 Guanajuato, Mexico
| | | | | | - F. Ferraro
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - L. Fields
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Filkins
- William and Mary, Williamsburg, VA 23187 USA
| | - F. Filthaut
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
- Radboud University, 6525 AJ Nijmegen, The Netherlands
| | | | - W. Flanagan
- University of Dallas, Irving, TX 75062-4736 USA
| | - B. Fleming
- Yale University, New Haven, CT 06520 USA
| | - R. Flight
- University of Rochester, Rochester, NY 14627 USA
| | - J. Fowler
- Duke University, Durham, NC 27708 USA
| | - W. Fox
- Indiana University, Bloomington, IN 47405 USA
| | - J. Franc
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - K. Francis
- Northern Illinois University, DeKalb, IL 60115 USA
| | - D. Franco
- Yale University, New Haven, CT 06520 USA
| | - J. Freeman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Freestone
- University of Manchester, Manchester, M13 9PL UK
| | - J. Fried
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - A. Friedland
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - S. Fuess
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - I. Furic
- University of Florida, Gainesville, FL 32611-8440 USA
| | - A. P. Furmanski
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - A. Gago
- Pontificia Universidad Católica del Perú, Lima, Peru
| | | | - A. Gallego-Ros
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - N. Gallice
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
- Università degli Studi di Milano, 20133 Milan, Italy
| | - V. Galymov
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - E. Gamberini
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - T. Gamble
- University of Sheffield, Sheffield, S3 7RH UK
| | - R. Gandhi
- Harish-Chandra Research Institute, Jhunsi, Allahabad, 211 019 India
| | - R. Gandrajula
- Michigan State University, East Lansing, MI 48824 USA
| | - S. Gao
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | | | - S. Gardiner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - G. Ge
- Columbia University, New York, NY 10027 USA
| | - B. Gelli
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | | | - S. Gent
- South Dakota State University, Brookings, SD 57007 USA
| | | | - D. Gibin
- Universtà degli Studi di Padova, 35131 Padua, Italy
| | - I. Gil-Botella
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - C. Girerd
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - A. K. Giri
- Indian Institute of Technology Hyderabad, Hyderabad, 502285 India
| | - D. Gnani
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - O. Gogota
- Kyiv National University, Kiev, 01601 Ukraine
| | - M. Gold
- University of New Mexico, Albuquerque, NM 87131 USA
| | - S. Gollapinni
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - K. Gollwitzer
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. A. Gomes
- Universidade Federal de Goias, Goiânia, GO 74690-900 Brazil
| | | | | | - F. Gonnella
- University of Birmingham, Birmingham, B15 2TT UK
| | | | | | - O. Goodwin
- University of Manchester, Manchester, M13 9PL UK
| | - S. Goswami
- Physical Research Laboratory, Ahmedabad, 380 009 India
| | - C. Gotti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | | | - C. Grace
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - M. Graham
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | | | - R. Gran
- University of Minnesota Duluth, Duluth, MN 55812 USA
| | - E. Granados
- Universidad de Guanajuato, C.P. 37000 Guanajuato, Mexico
| | - A. Grant
- Daresbury Laboratory, Cheshire, WA4 4AD UK
| | - C. Grant
- Boston University, Boston, MA 02215 USA
| | - D. Gratieri
- Fluminense Federal University, 9 Icaraí, Niterói, RJ 24220-900 Brazil
| | - P. Green
- University of Manchester, Manchester, M13 9PL UK
| | - S. Green
- University of Cambridge, Cambridge, CB3 0HE UK
| | - L. Greenler
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - M. Greenwood
- Oregon State University, Corvallis, OR 97331 USA
| | - J. Greer
- University of Bristol, Bristol, BS8 1TL UK
| | | | - M. Groh
- Indiana University, Bloomington, IN 47405 USA
| | | | - K. Grzelak
- University of Warsaw, 00-927 Warsaw, Poland
| | - W. Gu
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - V. Guarino
- Argonne National Laboratory, Argonne, IL 60439 USA
| | | | - A. Guglielmi
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - B. Guo
- University of South Carolina, Columbia, SC 29208 USA
| | | | | | - P. Guzowski
- University of Manchester, Manchester, M13 9PL UK
| | - M. M. Guzzo
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - S. Gwon
- Chung-Ang University, Seoul, 06974 South Korea
| | - A. Habig
- University of Minnesota Duluth, Duluth, MN 55812 USA
| | | | - H. Hadavand
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - R. Haenni
- University of Bern, 3012 Bern, Switzerland
| | - A. Hahn
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Haigh
- University of Warwick, Coventry, CV4 7AL UK
| | - J. Haiston
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - T. Hamernik
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - P. Hamilton
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - J. Han
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - K. Harder
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - D. A. Harris
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- York University, Toronto, M3J 1P3 Canada
| | | | - T. Hasegawa
- High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801 Japan
| | - R. Hatcher
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Hazen
- Boston University, Boston, MA 02215 USA
| | - A. Heavey
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - J. Heise
- Sanford Underground Research Facility, Lead, SD 57754 USA
| | - K. Hennessy
- University of Liverpool, Liverpool, L69 7ZE UK
| | - S. Henry
- University of Rochester, Rochester, NY 14627 USA
| | | | - K. Herner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Hertel
- University of California Irvine, Irvine, CA 92697 USA
| | - A. S. Hesam
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - J. Hewes
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - A. Higuera
- University of Houston, Houston, TX 77204 USA
| | - T. Hill
- Idaho State University, Pocatello, ID 83209 USA
| | | | - A. Himmel
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Hoff
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - C. Hohl
- University of Basel, 4056 Basel, Switzerland
| | - A. Holin
- University College London, London, WC1E 6BT UK
| | - E. Hoppe
- Pacific Northwest National Laboratory, Richland, WA 99352 USA
| | | | | | - A. Hourlier
- Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | - B. Howard
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Howell
- University of Rochester, Rochester, NY 14627 USA
| | - J. Huang
- University of Texas at Austin, Austin, TX 78712 USA
| | - J. Huang
- University of California Davis, Davis, CA 95616 USA
| | - J. Hugon
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - G. Iles
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - N. Ilic
- University of Toronto, Toronto, ON M5S 1A1 Canada
| | - A. M. Iliescu
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - R. Illingworth
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Ioannisian
- Yerevan Institute for Theoretical Physics and Modeling, 0036 Yerevan, Armenia
| | - R. Itay
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - A. Izmaylov
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - E. James
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - B. Jargowsky
- University of California Irvine, Irvine, CA 92697 USA
| | - F. Jediny
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | | | - X. Ji
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - L. Jiang
- Virginia Tech, Blacksburg, VA 24060 USA
| | - S. Jiménez
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - A. Jipa
- University of Bucharest, Bucharest, Romania
| | - A. Joglekar
- University of California Riverside, Riverside, CA 92521 USA
| | - C. Johnson
- Colorado State University, Fort Collins, CO 80523 USA
| | - R. Johnson
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - B. Jones
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - S. Jones
- University College London, London, WC1E 6BT UK
| | - C. K. Jung
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - T. Junk
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - Y. Jwa
- Columbia University, New York, NY 10027 USA
| | | | - A. Kaboth
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - I. Kadenko
- Kyiv National University, Kiev, 01601 Ukraine
| | - F. Kamiya
- Universidade Federal do ABC, Santo André, SP 09210-580 Brazil
| | | | - A. Karcher
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - M. Karolak
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | - Y. Karyotakis
- Laboratoire d’Annecy-le-Vieux de Physique des Particules, CNRS/IN2P3 and Université Savoie Mont Blanc, 74941 Annecy-le-Vieux, France
| | - S. Kasai
- National Institute of Technology, Kure College, Hiroshima, 737-8506 Japan
| | - S. P. Kasetti
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - L. Kashur
- Colorado State University, Fort Collins, CO 80523 USA
| | - N. Kazaryan
- Yerevan Institute for Theoretical Physics and Modeling, 0036 Yerevan, Armenia
| | - E. Kearns
- Boston University, Boston, MA 02215 USA
| | - P. Keener
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - K. J. Kelly
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Kemp
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - W. Ketchum
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - M. Khabibullin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - A. Khotjantsev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | | | - D. Kim
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - B. King
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - B. Kirby
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Kirby
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Klein
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - K. Koehler
- University of Wisconsin Madison, Madison, WI 53706 USA
| | | | - S. Kohn
- University of California Berkeley, Berkeley, CA 94720 USA
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | | | - M. Kordosky
- William and Mary, Williamsburg, VA 23187 USA
| | - T. Kosc
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - U. Kose
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | | | | | - I. Kreslo
- University of Bern, 3012 Bern, Switzerland
| | - Y. Kudenko
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | | | - S. Kulagin
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - J. Kumar
- University of Hawaii, Honolulu, HI 96822 USA
| | - R. Kumar
- Punjab Agricultural University, Ludhiana, 141004 India
| | - C. Kuruppu
- University of South Carolina, Columbia, SC 29208 USA
| | - V. Kus
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - T. Kutter
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - A. Lambert
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - K. Lande
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - C. E. Lane
- Drexel University, Philadelphia, PA 19104 USA
| | - K. Lang
- University of Texas at Austin, Austin, TX 78712 USA
| | | | - P. Lasorak
- University of Sussex, Brighton, BN1 9RH UK
| | - D. Last
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - C. Lastoria
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - A. Laundrie
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - A. Lawrence
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - I. Lazanu
- University of Bucharest, Bucharest, Romania
| | - R. LaZur
- Colorado State University, Fort Collins, CO 80523 USA
| | - T. Le
- Tufts University, Medford, MA 02155 USA
| | - J. Learned
- University of Hawaii, Honolulu, HI 96822 USA
| | - P. LeBrun
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - G. Lehmann Miotto
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - R. Lehnert
- Indiana University, Bloomington, IN 47405 USA
| | | | - M. Leitner
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - M. Leyton
- Institut de Fìsica d’Altes Energies, Barcelona, Spain
| | - L. Li
- University of California Irvine, Irvine, CA 92697 USA
| | - S. Li
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - S. W. Li
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - T. Li
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | - Y. Li
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - H. Liao
- Kansas State University, Manhattan, KS 66506 USA
| | - C. S. Lin
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - S. Lin
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - A. Lister
- University of Wisconsin Madison, Madison, WI 53706 USA
| | | | - J. Liu
- University of California Irvine, Irvine, CA 92697 USA
| | - S. Lockwitz
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - T. Loew
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - M. Lokajicek
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | - I. Lomidze
- Georgian Technical University, Tbilisi, Georgia
| | - K. Long
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - K. Loo
- University of Jyvaskyla, 40014 Jyväskylä, Finland
| | - D. Lorca
- University of Bern, 3012 Bern, Switzerland
| | - T. Lord
- University of Warwick, Coventry, CV4 7AL UK
| | | | - W. C. Louis
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - K. B. Luk
- University of California Berkeley, Berkeley, CA 94720 USA
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - X. Luo
- University of California Santa Barbara, Santa Barbara, CA 93106 USA
| | - N. Lurkin
- University of Birmingham, Birmingham, B15 2TT UK
| | - T. Lux
- Institut de Fìsica d’Altes Energies, Barcelona, Spain
| | - V. P. Luzio
- Universidade Federal do ABC, Santo André, SP 09210-580 Brazil
| | - D. MacFarland
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - A. A. Machado
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - P. Machado
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - J. R. Macier
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Maddalena
- Laboratori Nazionali del Gran Sasso, L’Aquila, AQ Italy
| | - P. Madigan
- University of California Berkeley, Berkeley, CA 94720 USA
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - S. Magill
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - K. Mahn
- Michigan State University, East Lansing, MI 48824 USA
| | - A. Maio
- Faculdade de Ciências da Universidade de Lisboa-FCUL, 1749-016 Lisbon, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003, Lisbon and, 3004-516 Coimbra, Portugal
| | | | - G. Mandrioli
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - J. Maneira
- Faculdade de Ciências da Universidade de Lisboa-FCUL, 1749-016 Lisbon, Portugal
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003, Lisbon and, 3004-516 Coimbra, Portugal
| | - L. Manenti
- University College London, London, WC1E 6BT UK
| | - S. Manly
- University of Rochester, Rochester, NY 14627 USA
| | - A. Mann
- Tufts University, Medford, MA 02155 USA
| | | | | | - A. Marchionni
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - W. Marciano
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - D. Marfatia
- University of Hawaii, Honolulu, HI 96822 USA
| | | | - J. Maricic
- University of Hawaii, Honolulu, HI 96822 USA
| | - F. Marinho
- Universidade Federal de São Carlos, Araras, SP 13604-900 Brazil
| | - A. D. Marino
- University of Colorado Boulder, Boulder, CO 80309 USA
| | - M. Marshak
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - C. Marshall
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | | | - J. Marteau
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - J. Martin-Albo
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - N. Martinez
- Kansas State University, Manhattan, KS 66506 USA
| | | | - S. Martynenko
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - K. Mason
- Tufts University, Medford, MA 02155 USA
| | - A. Mastbaum
- Rutgers University, Piscataway, NJ 08854 USA
| | - M. Masud
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - S. Matsuno
- University of Hawaii, Honolulu, HI 96822 USA
| | - J. Matthews
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - C. Mauger
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - N. Mauri
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | | | - R. Mazza
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - A. Mazzacane
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Mazzucato
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | - E. McCluskey
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - N. McConkey
- University of Manchester, Manchester, M13 9PL UK
| | | | - C. McGrew
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - A. McNab
- University of Manchester, Manchester, M13 9PL UK
| | - A. Mefodiev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - P. Mehta
- Jawaharlal Nehru University, New Delhi, 110067 India
| | - P. Melas
- University of Athens, 157 84 Zografou, Greece
| | - M. Mellinato
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - O. Mena
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - S. Menary
- York University, Toronto, M3J 1P3 Canada
| | - H. Mendez
- University of Puerto Rico, Mayagüez, PR 00681 USA
| | - A. Menegolli
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - G. Meng
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | | | - W. Metcalf
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - M. Mewes
- Indiana University, Bloomington, IN 47405 USA
| | - H. Meyer
- Wichita State University, Wichita, KS 67260 USA
| | - T. Miao
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Michna
- South Dakota State University, Brookings, SD 57007 USA
| | - T. Miedema
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
- Radboud University, 6525 AJ Nijmegen, The Netherlands
| | - J. Migenda
- University of Sheffield, Sheffield, S3 7RH UK
| | - R. Milincic
- University of Hawaii, Honolulu, HI 96822 USA
| | - W. Miller
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - J. Mills
- Tufts University, Medford, MA 02155 USA
| | - C. Milne
- Idaho State University, Pocatello, ID 83209 USA
| | - O. Mineev
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - O. G. Miranda
- Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav), Mexico City, Mexico
| | - S. Miryala
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - C. S. Mishra
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. R. Mishra
- University of South Carolina, Columbia, SC 29208 USA
| | - A. Mislivec
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - D. Mladenov
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - I. Mocioiu
- Pennsylvania State University, University Park, PA 16802 USA
| | - K. Moffat
- Durham University, Durham, DH1 3LE UK
| | - N. Moggi
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - R. Mohanta
- University of Hyderabad, Gachibowli, Hyderabad, 500 046 India
| | - T. A. Mohayai
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - N. Mokhov
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Molina
- Universidad Nacional de Asunción, San Lorenzo, Paraguay
| | | | - A. Montanari
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - C. Montanari
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - D. Montanari
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. M. Montano Zetina
- Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav), Mexico City, Mexico
| | - J. Moon
- Massachusetts Institute of Technology, Cambridge, MA 02139 USA
| | - M. Mooney
- Colorado State University, Fort Collins, CO 80523 USA
| | - A. Moor
- University of Cambridge, Cambridge, CB3 0HE UK
| | - D. Moreno
- Universidad Antonio Nariño, Bogotá, Colombia
| | - B. Morgan
- University of Warwick, Coventry, CV4 7AL UK
| | - C. Morris
- University of Houston, Houston, TX 77204 USA
| | - C. Mossey
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Motuk
- University College London, London, WC1E 6BT UK
| | - C. A. Moura
- Universidade Federal do ABC, Santo André, SP 09210-580 Brazil
| | - J. Mousseau
- University of Michigan, Ann Arbor, MI 48109 USA
| | - W. Mu
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Mualem
- California Institute of Technology, Pasadena, CA 91125 USA
| | - J. Mueller
- Colorado State University, Fort Collins, CO 80523 USA
| | - M. Muether
- Wichita State University, Wichita, KS 67260 USA
| | - S. Mufson
- Indiana University, Bloomington, IN 47405 USA
| | - F. Muheim
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | - A. Muir
- Daresbury Laboratory, Cheshire, WA4 4AD UK
| | - M. Mulhearn
- University of California Davis, Davis, CA 95616 USA
| | - H. Muramatsu
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | | | - J. Musser
- Indiana University, Bloomington, IN 47405 USA
| | | | - S. Nagu
- University of Lucknow, Lucknow, Uttar Pradesh 226007 India
| | - M. Nalbandyan
- Yerevan Institute for Theoretical Physics and Modeling, 0036 Yerevan, Armenia
| | - R. Nandakumar
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - D. Naples
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - S. Narita
- Iwate University, Morioka, Iwate 020-8551 Japan
| | - D. Navas-Nicolás
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - N. Nayak
- University of California Irvine, Irvine, CA 92697 USA
| | | | - L. Necib
- California Institute of Technology, Pasadena, CA 91125 USA
| | - K. Negishi
- Iwate University, Morioka, Iwate 020-8551 Japan
| | | | - J. Nesbit
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - M. Nessi
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - D. Newbold
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - M. Newcomer
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - D. Newhart
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Nichol
- University College London, London, WC1E 6BT UK
| | - E. Niner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - A. Norman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Norrick
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Northrop
- University of Chicago, Chicago, IL 60637 USA
| | - P. Novella
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | | | - M. Oberling
- Argonne National Laboratory, Argonne, IL 60439 USA
| | | | - A. Olivier
- University of Rochester, Rochester, NY 14627 USA
| | - Y. Onel
- University of Iowa, Iowa City, IA 52242 USA
| | | | - J. Ott
- University of California Irvine, Irvine, CA 92697 USA
| | - L. Pagani
- University of California Davis, Davis, CA 95616 USA
| | - S. Pakvasa
- University of Hawaii, Honolulu, HI 96822 USA
| | - O. Palamara
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Palestini
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - J. M. Paley
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Pallavicini
- Università degli Studi di Genova, Genoa, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - C. Palomares
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - E. Pantic
- University of California Davis, Davis, CA 95616 USA
| | - V. Paolone
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | | | - R. Papaleo
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - A. Papanestis
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | | | - J. C. Park
- Chungnam National University, Daejeon, 34134 South Korea
| | - S. Parke
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - Z. Parsa
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Parvu
- University of Bucharest, Bucharest, Romania
| | | | - L. Pasqualini
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - J. Pasternak
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - J. Pater
- University of Manchester, Manchester, M13 9PL UK
| | - C. Patrick
- University College London, London, WC1E 6BT UK
| | - L. Patrizii
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | | | - S. J. Patton
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - T. Patzak
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - A. Paudel
- Kansas State University, Manhattan, KS 66506 USA
| | - B. Paulos
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - L. Paulucci
- Universidade Federal do ABC, Santo André, SP 09210-580 Brazil
| | - Z. Pavlovic
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - G. Pawloski
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - D. Payne
- University of Liverpool, Liverpool, L69 7ZE UK
| | - V. Pec
- University of Sheffield, Sheffield, S3 7RH UK
| | | | - Y. Penichot
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | - E. Pennacchio
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - A. Penzo
- University of Iowa, Iowa City, IA 52242 USA
| | - O. L. G. Peres
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - J. Perry
- University of Edinburgh, Edinburgh, EH8 9YL UK
| | | | - G. Pessina
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
| | - G. Petrillo
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - C. Petta
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - R. Petti
- University of South Carolina, Columbia, SC 29208 USA
| | - F. Piastra
- University of Bern, 3012 Bern, Switzerland
| | - L. Pickering
- Michigan State University, East Lansing, MI 48824 USA
| | - F. Pietropaolo
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - J. Pillow
- University of Warwick, Coventry, CV4 7AL UK
| | - J. Pinzino
- University of Toronto, Toronto, ON M5S 1A1 Canada
| | - R. Plunkett
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Poling
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - X. Pons
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - S. Pordes
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Potekhin
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - R. Potenza
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | | | - J. Pozimski
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - M. Pozzato
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - S. Prakash
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - T. Prakash
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - S. Prince
- Harvard University, Cambridge, MA 02138 USA
| | - G. Prior
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003, Lisbon and, 3004-516 Coimbra, Portugal
| | - D. Pugnere
- Institut de Physique des 2 Infinis de Lyon, 69622 Villeurbanne, France
| | - K. Qi
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - X. Qian
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - J. L. Raaf
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - R. Raboanary
- University of Antananarivo, 101 Antananarivo, Madagascar
| | - V. Radeka
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | | | - A. Rafique
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - E. Raguzin
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Rai
- University of Warwick, Coventry, CV4 7AL UK
| | | | - I. Rakhno
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | | | | | - R. Rameika
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - B. Ramson
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Rappoldi
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - G. Raselli
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - P. Ratoff
- Lancaster University, Lancaster, LA1 4YB UK
| | - S. Ravat
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - H. Razafinime
- University of Antananarivo, 101 Antananarivo, Madagascar
| | - J. S. Real
- University Grenoble Alpes, CNRS, Grenoble INP, LPSC-IN2P3, 38000 Grenoble, France
| | - B. Rebel
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - D. Redondo
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | | | - T. Rehak
- Drexel University, Philadelphia, PA 19104 USA
| | - J. Reichenbacher
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - S. D. Reitzner
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Renshaw
- University of Houston, Houston, TX 77204 USA
| | - S. Rescia
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - F. Resnati
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - G. Riccobene
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | | | - K. Rielage
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | | | - D. Rivera
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - L. Rochester
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - M. Roda
- University of Liverpool, Liverpool, L69 7ZE UK
| | | | | | | | | | - H. Rogers
- Colorado State University, Fort Collins, CO 80523 USA
| | | | - M. Rossella
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
- Università degli Studi di Pavia, 27100 Pavia, PV Italy
| | - J. Rout
- Jawaharlal Nehru University, New Delhi, 110067 India
| | - S. Roy
- Harish-Chandra Research Institute, Jhunsi, Allahabad, 211 019 India
| | | | - C. Rubbia
- Gran Sasso Science Institute, L’Aquila, Italy
| | - B. Russell
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - J. Russell
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | | | - R. Saakyan
- University College London, London, WC1E 6BT UK
| | - S. Sacerdoti
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - T. Safford
- Michigan State University, East Lansing, MI 48824 USA
| | - N. Sahu
- Indian Institute of Technology Hyderabad, Hyderabad, 502285 India
| | - P. Sala
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
| | - N. Samios
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | | | - D. Sankey
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - S. Santana
- University of Puerto Rico, Mayagüez, PR 00681 USA
| | | | | | - P. Sapienza
- Istituto Nazionale di Fisica Nucleare Laboratori Nazionali del Sud, 95123 Catania, Italy
| | - C. Sarasty
- University of Cincinnati, Cincinnati, OH 45221 USA
| | | | - G. Savage
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - V. Savinov
- University of Pittsburgh, Pittsburgh, PA 15260 USA
| | - A. Scaramelli
- Istituto Nazionale di Fisica Nucleare Sezione di Pavia, 27100 Pavia, Italy
| | - A. Scarff
- University of Sheffield, Sheffield, S3 7RH UK
| | - A. Scarpelli
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - T. Schaffer
- University of Minnesota Duluth, Duluth, MN 55812 USA
| | - H. Schellman
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
- Oregon State University, Corvallis, OR 97331 USA
| | - P. Schlabach
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - D. Schmitz
- University of Chicago, Chicago, IL 60637 USA
| | | | - A. Schukraft
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Segreto
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - J. Sensenig
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | - I. Seong
- University of California Irvine, Irvine, CA 92697 USA
| | - A. Sergi
- University of Birmingham, Birmingham, B15 2TT UK
| | | | | | | | - S. Shafaq
- Jawaharlal Nehru University, New Delhi, 110067 India
| | - M. Shamma
- University of California Riverside, Riverside, CA 92521 USA
| | | | - R. Sharma
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - T. Shaw
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - S. Shin
- Jeonbuk National University, Jeonju, Jeonrabuk-do 54896 South Korea
| | - D. Shooltz
- Michigan State University, East Lansing, MI 48824 USA
| | - R. Shrock
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - L. Simard
- Laboratoire de l’Accélérateur Linéaire, 91440 Orsay, France
| | - N. Simos
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - G. Sinev
- Duke University, Durham, NC 27708 USA
| | - J. Singh
- University of Lucknow, Lucknow, Uttar Pradesh 226007 India
| | - J. Singh
- University of Lucknow, Lucknow, Uttar Pradesh 226007 India
| | - V. Singh
- Banaras Hindu University, Varanasi, 221 005 India
- Central University of South Bihar, Gaya, 824236 India
| | - R. Sipos
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | | | - G. Sirri
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - A. Sitraka
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - K. Siyeon
- Chung-Ang University, Seoul, 06974 South Korea
| | | | - A. Smith
- Duke University, Durham, NC 27708 USA
| | - A. Smith
- University of Cambridge, Cambridge, CB3 0HE UK
| | - E. Smith
- Indiana University, Bloomington, IN 47405 USA
| | - P. Smith
- Indiana University, Bloomington, IN 47405 USA
| | - J. Smolik
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - M. Smy
- University of California Irvine, Irvine, CA 92697 USA
| | - P. Snopok
- Illinois Institute of Technology, Chicago, IL 60616 USA
| | - M. Soares Nunes
- Universidade Estadual de Campinas, Campinas, SP 13083-970 Brazil
| | - H. Sobel
- University of California Irvine, Irvine, CA 92697 USA
| | | | | | | | - N. Solomey
- Wichita State University, Wichita, KS 67260 USA
| | - V. Solovov
- Laboratório de Instrumentação e Física Experimental de Partículas, 1649-003, Lisbon and, 3004-516 Coimbra, Portugal
| | - W. E. Sondheim
- Los Alamos National Laboratory, Los Alamos, NM 87545 USA
| | - M. Sorel
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - J. Soto-Oton
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - A. Sousa
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - K. Soustruznik
- Institute of Particle and Nuclear Physics of the Faculty of Mathematics and Physics of the Charles University, 180 00 Prague 8, Czech Republic
| | | | - M. Spanu
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - J. Spitz
- University of Michigan, Ann Arbor, MI 48109 USA
| | | | | | - R. Staley
- University of Birmingham, Birmingham, B15 2TT UK
| | - M. Stancari
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - L. Stanco
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - H. M. Steiner
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - J. Stewart
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - J. Stock
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - F. Stocker
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - D. Stocks
- Stanford University, Stanford, CA 94305 USA
| | - T. Stokes
- Louisiana State University, Baton Rouge, LA 70803 USA
| | - M. Strait
- University of Minnesota Twin Cities, Minneapolis, MN 55455 USA
| | - T. Strauss
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Striganov
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - A. Stuart
- Universidad de Colima, Colima, Mexico
| | - D. Summers
- University of Mississippi, University, MS 38677 USA
| | - A. Surdo
- Istituto Nazionale di Fisica Nucleare Sezione di Lecce, 73100 Lecce, Italy
| | - V. Susic
- University of Basel, 4056 Basel, Switzerland
| | - L. Suter
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - C. M. Sutera
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - R. Svoboda
- University of California Davis, Davis, CA 95616 USA
| | - B. Szczerbinska
- Texas A&M University-Corpus Christi, Corpus Christi, TX 78412 USA
| | - A. M. Szelc
- University of Manchester, Manchester, M13 9PL UK
| | - R. Talaga
- Argonne National Laboratory, Argonne, IL 60439 USA
| | - H. A. Tanaka
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | | | - A. Tapper
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - S. Tariq
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - E. Tatar
- Idaho State University, Pocatello, ID 83209 USA
| | - R. Tayloe
- Indiana University, Bloomington, IN 47405 USA
| | - A. M. Teklu
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - M. Tenti
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - K. Terao
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - C. A. Ternes
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - F. Terranova
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - G. Testera
- Istituto Nazionale di Fisica Nucleare Sezione di Genova, 16146 Genoa, GE Italy
| | - A. Thea
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | | | - C. Thorn
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - S. C. Timm
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Todd
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - A. Tonazzo
- Université de Paris, CNRS, Astroparticule et Cosmologie, 75006 Paris, France
| | - M. Torti
- Istituto Nazionale di Fisica Nucleare Sezione di Milano Bicocca, 3, 20126 Milan, Italy
- Università del Milano-Bicocca, 20126 Milan, Italy
| | - M. Tortola
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - F. Tortorici
- Università di Catania, 2, 95131 Catania, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Catania, 95123 Catania, Italy
| | - D. Totani
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - M. Toups
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - J. Trevor
- California Institute of Technology, Pasadena, CA 91125 USA
| | | | - Y.-T. Tsai
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | | | - K. V. Tsang
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - N. Tsverava
- Georgian Technical University, Tbilisi, Georgia
| | - S. Tufanli
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - C. Tull
- Lawrence Berkeley National Laboratory, Berkeley, CA 94720 USA
| | - E. Tyley
- University of Sheffield, Sheffield, S3 7RH UK
| | - M. Tzanov
- Louisiana State University, Baton Rouge, LA 70803 USA
| | | | - J. Urheim
- Indiana University, Bloomington, IN 47405 USA
| | - T. Usher
- SLAC National Accelerator Laboratory, Menlo Park, CA 94025 USA
| | - M. R. Vagins
- Kavli Institute for the Physics and Mathematics of the Universe, Kashiwa, Chiba 277-8583 Japan
| | - P. Vahle
- William and Mary, Williamsburg, VA 23187 USA
| | - G. A. Valdiviesso
- Universidade Federal de Alfenas, Poços de Caldas, MG 37715-400 Brazil
| | - E. Valencia
- William and Mary, Williamsburg, VA 23187 USA
| | - Z. Vallari
- California Institute of Technology, Pasadena, CA 91125 USA
| | - J. W. F. Valle
- Instituto de Fisica Corpuscular, 46980 Paterna, Valencia Spain
| | - S. Vallecorsa
- CERN, The European Organization for Nuclear Research, 1211 Meyrin, Switzerland
| | - R. Van Berg
- University of Pennsylvania, Philadelphia, PA 19104 USA
| | | | | | - F. Varanini
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - D. Vargas
- Institut de Fìsica d’Altes Energies, Barcelona, Spain
| | - G. Varner
- University of Hawaii, Honolulu, HI 96822 USA
| | - J. Vasel
- Indiana University, Bloomington, IN 47405 USA
| | - G. Vasseur
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | - K. Vaziri
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - S. Ventura
- Istituto Nazionale di Fisica Nucleare Sezione di Padova, 35131 Padua, Italy
| | - A. Verdugo
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, 28040 Madrid, Spain
| | - S. Vergani
- University of Cambridge, Cambridge, CB3 0HE UK
| | - M. A. Vermeulen
- Nikhef National Institute of Subatomic Physics, 1098 XG Amsterdam, The Netherlands
| | - M. Verzocchi
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | | | - C. Vignoli
- Laboratori Nazionali del Gran Sasso, L’Aquila, AQ Italy
| | - C. Vilela
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - B. Viren
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - T. Vrba
- Czech Technical University, 115 19 Prague 1, Czech Republic
| | - T. Wachala
- H. Niewodniczański Institute of Nuclear Physics, Polish Academy of Sciences, Cracow, Poland
| | - A. V. Waldron
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - M. Wallbank
- University of Cincinnati, Cincinnati, OH 45221 USA
| | - H. Wang
- University of California Los Angeles, Los Angeles, CA 90095 USA
| | - J. Wang
- University of California Davis, Davis, CA 95616 USA
| | - Y. Wang
- University of California Los Angeles, Los Angeles, CA 90095 USA
| | - Y. Wang
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | | | - D. Warner
- Colorado State University, Fort Collins, CO 80523 USA
| | - M. Wascko
- Imperial College of Science Technology and Medicine, London, SW7 2BZ UK
| | - D. Waters
- University College London, London, WC1E 6BT UK
| | - A. Watson
- University of Birmingham, Birmingham, B15 2TT UK
| | | | - A. Weber
- University of Oxford, Oxford, OX1 3RH UK
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - M. Weber
- University of Bern, 3012 Bern, Switzerland
| | - H. Wei
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | | | - D. Wenman
- University of Wisconsin Madison, Madison, WI 53706 USA
| | | | - M. R. While
- South Dakota School of Mines and Technology, Rapid City, SD 57701 USA
| | - A. White
- University of Texas at Arlington, Arlington, TX 76019 USA
| | | | | | - M. J. Wilking
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | | | - Z. Williams
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - F. Wilson
- STFC Rutherford Appleton Laboratory, Didcot, OX11 0QX UK
| | - R. J. Wilson
- Colorado State University, Fort Collins, CO 80523 USA
| | | | | | - K. Wood
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - L. Wood
- Pacific Northwest National Laboratory, Richland, WA 99352 USA
| | - E. Worcester
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Worcester
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - C. Wret
- University of Rochester, Rochester, NY 14627 USA
| | - W. Wu
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - W. Wu
- University of California Irvine, Irvine, CA 92697 USA
| | - Y. Xiao
- University of California Irvine, Irvine, CA 92697 USA
| | - G. Yang
- Stony Brook University, SUNY, Stony Brook, NY 11794 USA
| | - T. Yang
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - N. Yershov
- Institute for Nuclear Research of the Russian Academy of Sciences, Moscow, 117312 Russia
| | - K. Yonehara
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - T. Young
- University of North Dakota, Grand Forks, ND 58202-8357 USA
| | - B. Yu
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - J. Yu
- University of Texas at Arlington, Arlington, TX 76019 USA
| | - R. Zaki
- York University, Toronto, M3J 1P3 Canada
| | - J. Zalesak
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | - L. Zambelli
- Laboratoire d’Annecy-le-Vieux de Physique des Particules, CNRS/IN2P3 and Université Savoie Mont Blanc, 74941 Annecy-le-Vieux, France
| | - B. Zamorano
- University of Granada and CAFPE, 18002 Granada, Spain
| | - A. Zani
- Istituto Nazionale di Fisica Nucleare Sezione di Milano, 20133 Milan, Italy
| | - L. Zazueta
- William and Mary, Williamsburg, VA 23187 USA
| | - G. P. Zeller
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - J. Zennamo
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| | - K. Zeug
- University of Wisconsin Madison, Madison, WI 53706 USA
| | - C. Zhang
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - M. Zhao
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - Y. Zhao
- University of Utah, Salt Lake City, UT 84112 USA
| | - E. Zhivun
- Brookhaven National Laboratory, Upton, NY 11973 USA
| | - G. Zhu
- Ohio State University, Columbus, OH 43210 USA
| | | | - M. Zito
- CEA/Saclay, IRFU Institut de Recherche sur les Lois Fondamentales de l’Univers, 91191 Gif-sur-Yvette Cedex, France
| | - S. Zucchelli
- Università del Bologna, 40127 Bologna, Italy
- Istituto Nazionale di Fisica Nucleare Sezione di Bologna, 40127 Bologna, BO Italy
| | - J. Zuklin
- Institute of Physics, Czech Academy of Sciences, 182 00 Prague 8, Czech Republic
| | - V. Zutshi
- Northern Illinois University, DeKalb, IL 60115 USA
| | - R. Zwaska
- Fermi National Accelerator Laboratory, Batavia, IL 60510 USA
| |
Collapse
|
18
|
Turgeon R, Youngson E, Graham M. ASSOCIATION OF TICAGRELOR WITH RISK OF PNEUMONIA: A POPULATION-BASED COHORT STUDY. Can J Cardiol 2020. [DOI: 10.1016/j.cjca.2020.07.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
19
|
Szamosi JC, Forbes JD, Copeland JK, Knox NC, Shekarriz S, Rossi L, Graham M, Bonner C, Guttman DS, Van Domselaar G, Surette MG, Bernstein CN. Assessment of Inter-Laboratory Variation in the Characterization and Analysis of the Mucosal Microbiota in Crohn's Disease and Ulcerative Colitis. Front Microbiol 2020; 11:2028. [PMID: 32973734 PMCID: PMC7472644 DOI: 10.3389/fmicb.2020.02028] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Accepted: 07/31/2020] [Indexed: 01/04/2023] Open
Abstract
Background In studies evaluating the microbiome, numerous factors can contribute to technical variability. These factors include DNA extraction methodology, sequencing protocols, and data analysis strategies. We sought to evaluate the impact these factors have on the results obtained when the sequence data are independently generated and analyzed by different laboratories. Methods To evaluate the effect of technical variability, we used human intestinal biopsy samples resected from individuals diagnosed with an inflammatory bowel disease (IBD), including Crohn’s disease (n = 12) and ulcerative colitis (n = 10), and those without IBD (n = 10). Matched samples from each participant were sent to three laboratories and studied using independent protocols for DNA extraction, library preparation, targeted-amplicon sequencing of a 16S rRNA gene hypervariable region, and processing of sequence data. We looked at two measures of interest – Bray–Curtis PERMANOVA R2 values and log2 fold-change estimates of the 25 most-abundant taxa – to assess variation in the results produced by each laboratory, as well the relative contribution to variation from the different extraction, sequencing, and analysis steps used to generate these measures. Results The R2 values and estimated differential abundance associated with diagnosis were consistent across datasets that used different DNA extraction and sequencing protocols, and within datasets that pooled samples from multiple protocols; however, variability in bioinformatic processing of sequence data led to changes in R2 values and inconsistencies in taxonomic assignment and abundance estimates. Conclusion Although the contribution of DNA extraction and sequencing methods to variability were observable, we find that results can be robust to the various extraction and sequencing approaches used in our study. Differences in data processing methods have a larger impact on results, making comparison among studies less reliable and the combined analysis of bioinformatically processed samples nearly impossible. Our results highlight the importance of making raw sequence data available to facilitate combined and comparative analyses of published studies using common data processing protocols. Study methodologies should provide detailed data processing methods for validation, interpretability, reproducibility, and comparability.
Collapse
Affiliation(s)
- Jake C Szamosi
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Jessica D Forbes
- Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.,IBD Clinical and Research Centre, University of Manitoba, Winnipeg, MB, Canada.,National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
| | - Julia K Copeland
- Centre for the Analysis of Genome Evolution and Function, University of Toronto, Toronto, ON, Canada
| | - Natalie C Knox
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.,Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
| | - Shahrokh Shekarriz
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Laura Rossi
- Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Morag Graham
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.,Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
| | - Christine Bonner
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
| | - David S Guttman
- Centre for the Analysis of Genome Evolution and Function, University of Toronto, Toronto, ON, Canada
| | - Gary Van Domselaar
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada.,Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada
| | - Michael G Surette
- Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada
| | - Charles N Bernstein
- Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.,IBD Clinical and Research Centre, University of Manitoba, Winnipeg, MB, Canada
| |
Collapse
|
20
|
Gouda P, Graham M. PERI-OPERATIVE CARDIAC RISK ASSESSMENT PRIOR TO NON-CARDIAC SURGERY IN ALBERTA. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
21
|
Mathew A, Youngson E, Wirzba B, Graham M. THE TRAJECTORY OF FRAILTY SCORES OVER THE COURSE OF CARDIAC REHABILITATION. Can J Cardiol 2019. [DOI: 10.1016/j.cjca.2019.07.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
22
|
Abstract
The ProtoDUNE-SP is a single-phase liquid argon time projection chamber (LArTPC) prototype for the Deep Underground Neutrino Experiment (DUNE). Signals from 15,360 electronic channels are received by 60 Reconfigurable Cluster Elements (RCEs), which are processing elements designed at SLAC for a wide range of applications and are based upon the “system-onchip” Xilinx Zynq family of FPGAs. The RCEs are housed in industry-standard ATCA shelves on a custom blade, called the Cluster on Board (COB). The RCE platform and its processing functions for the ProtoDUNE-SP will be presented.
Collapse
|
23
|
Tsang RSW, Shuel M, Cronin K, Deng S, Whyte K, Marchand-Austin A, Ma J, Bolotin S, Crowcroft N, Schwartz K, Van Domselaar G, Graham M, Jamieson FB. The evolving nature of Bordetella pertussis in Ontario, Canada, 2009-2017: strains with shifting genotypes and pertactin deficiency. Can J Microbiol 2019; 65:823-830. [PMID: 31295416 DOI: 10.1139/cjm-2019-0128] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
This study examined the evolving nature of Bordetella pertussis in Ontario, Canada, by characterizing isolates for their genotypes and expression of pertactin (PRN). From 2009 to 2017, 413 B. pertussis were cultured from pertussis cases at the Public Health Ontario Laboratory. Their genotypes were determined by partial gene sequence analysis of their virulence and (or) vaccine antigens: filamentous haemagglutinin, PRN, fimbriae 3, and pertussis toxin, including the promoter region. Expression of PRN was measured by Western immunoblot. Two predominant genotypes, ST-1 and ST-2, were found throughout the study and were responsible for 47.5% and 46.3% of all case isolates, respectively. The prevalence of ST-1 appeared to fluctuate from 80.3% in 2009 to 20.0% in 2014 and 58.5% in 2017, while the prevalence of ST-2 changed from 18.4% in 2009 to 80.0% in 2014 and 26.2% in 2017. A PRN-deficient strain was first noted in 2011 (16.7%), and its prevalence increased to 70.8% in 2016 but decreased to 46.2% in 2017. More ST-2 (46.6%) than ST-1 (16.8%) strains were associated with PRN deficiency. Newer ST-21 and ST-22 found in 2015-2017 were uniformly PRN deficient. The impact of the evolving nature of B. pertussis on disease epidemiology requires further longitudinal studies.
Collapse
Affiliation(s)
- Raymond S W Tsang
- Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
| | - Michelle Shuel
- Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
| | - Kirby Cronin
- Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada.,Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada
| | - Saul Deng
- Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
| | - Kathleen Whyte
- Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
| | - Alex Marchand-Austin
- Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada
| | - Jennifer Ma
- Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada
| | - Shelly Bolotin
- Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada.,University of Toronto, Toronto, Ontario, Canada
| | - Natasha Crowcroft
- Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada.,University of Toronto, Toronto, Ontario, Canada
| | - Kevin Schwartz
- Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada
| | - Gary Van Domselaar
- Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
| | - Morag Graham
- Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba, Canada
| | - Frances B Jamieson
- Public Health Ontario Laboratory, Public Health Ontario, Toronto, Ontario, Canada.,University of Toronto, Toronto, Ontario, Canada
| |
Collapse
|
24
|
McAlister FA, Youngson E, Jacka M, Graham M, Conen D, Chan M, Szczeklik W, Alonso-Coello P, Devereaux PJ. A comparison of four risk models for the prediction of cardiovascular complications in patients with a history of atrial fibrillation undergoing non-cardiac surgery. Anaesthesia 2019; 75:27-36. [PMID: 31282570 DOI: 10.1111/anae.14777] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/14/2019] [Indexed: 02/06/2023]
Abstract
It is unclear how best to predict peri-operative cardiovascular risk in patients with atrial fibrillation undergoing non-cardiac surgery. This study examined the accuracy of the revised cardiac risk index and three atrial fibrillation thrombo-embolic risk models for predicting 30-day cardiovascular events after non-cardiac surgery in patients with a pre-operative history of atrial fibrillation. We conducted a prospective cohort study in 28 centres from 2007 to 2013 of 40,004 patients ≥ 45 years of age undergoing inpatient non-cardiac surgery who were followed until 30 days after surgery for cardiovascular events (defined as myocardial injury, heart failure, stroke, resuscitated cardiac arrest or cardiovascular death). The 2088 patients with a pre-operative history of atrial fibrillation were at higher risk of peri-operative cardiovascular events compared with the 34,830 patients without a history of atrial fibrillation (29% vs. 13%, respectively, adjusted odds ratio 1.30 (95%CI 1.17-1.45). Compared with the revised cardiac risk index (c-index 0.60), all atrial fibrillation thrombo-embolic risk scores were significantly better at predicting peri-operative cardiovascular events: CHADS2 (c-index 0.62); CHA2 DS2 -VASc (c-index 0.63); and R2 CHADS2 (c-index 0.65), respectively. Although the three thrombo-embolic risk prediction models were significantly better than the revised cardiac risk index for prediction of peri-operative cardiovascular events, none of the four models exhibited strong discrimination metrics. There remains a need to develop a better peri-operative risk prediction model.
Collapse
Affiliation(s)
- F A McAlister
- Alberta SPOR Support Unit, University of Alberta, Edmonton, AB, Canada.,General Internal Medicine, University of Alberta, Edmonton, AB, Canada
| | - E Youngson
- Alberta SPOR Support Unit, University of Alberta, Edmonton, AB, Canada
| | - M Jacka
- Critical Care Medicine, University of Alberta, Edmonton, AB, Canada
| | - M Graham
- Cardiology, Department of Medicine, University of Alberta, Edmonton, AB, Canada
| | - D Conen
- Population Health Research Institute, McMaster University, Hamilton, ON, Canada
| | - M Chan
- Department of Anaesthesia and Intensive Care, Chinese University of Hong Kong, Hong Kong
| | - W Szczeklik
- Jagiellonian University Medical College, Department of Intensive Care and Peri-operative Medicine, Kraków, Poland
| | - P Alonso-Coello
- Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau (IIB-Sant Pau), CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | - P J Devereaux
- Population Health Research Institute, McMaster University, Hamilton, ON, Canada
| | | |
Collapse
|
25
|
Graham M, Chan WY, Hill P. Lesion distribution in cases of canine atopic dermatitis in South Australia. Aust Vet J 2019; 97:262-267. [PMID: 31209859 DOI: 10.1111/avj.12828] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Revised: 12/18/2018] [Accepted: 02/20/2019] [Indexed: 11/26/2022]
Abstract
OBJECTIVE To determine the lesion distribution patterns in different breeds of dogs affected by atopic dermatitis in South Australia. METHODS The presence or absence of erythematous skin lesions in 267 cases of canine atopic dermatitis (CAD) was recorded across 36 anatomical sites. Breeds represented by ≥ 9 dogs were included in the analysis. The percentage of dogs showing lesions at each of the body sites was calculated and illustrated on colour-coded diagrams. Variations in affected body sites within and between breeds were compared using Kruskal-Wallis ANOVA and Dunn's multiple comparison tests. RESULTS The prevalence of skin lesions at different body sites differed significantly both in the population as a whole and within breeds. The sites affected in ≥ 75% dogs were the dorsal and ventral aspects of the front and hind paws. The sites affected in 50-74% were the medial pinnae, axillae, ventral chest, abdomen and perineum. Sites affected in 25-49% of dogs included the face, periocular region and forelimb. Remaining body sites were affected in < 25% of dogs. Analysis at the breed level revealed some differences from this standard distribution pattern. CONCLUSION The results of this study confirmed the typical lesion distributions seen in CAD and highlighted some subtle differences in breeds commonly seen in South Australia. This will be useful for clinical practitioners in prioritising differential diagnoses for pruritic skin conditions.
Collapse
Affiliation(s)
- M Graham
- School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, South Australia, 5371, Australia
| | - W Y Chan
- School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, South Australia, 5371, Australia
| | - P Hill
- School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, South Australia, 5371, Australia
| |
Collapse
|
26
|
Sheehan NK, Kellihan HB, Yarnall B, Graham M, Moore F. Septic pericarditis and pericardial abscess secondary to a migrating foreign body in a dog. J Vet Cardiol 2019; 23:122-128. [PMID: 31174722 DOI: 10.1016/j.jvc.2019.03.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 03/14/2019] [Accepted: 03/26/2019] [Indexed: 11/30/2022]
Abstract
Abscess formation in the pericardial space has been described as a rare complication of trauma, congenital defects, penetrating foreign body, or extension of local myocardial infection in the dog. Presented here is a case of a juvenile dog with septic pericardial effusion secondary to an isolated intrapericardial abscess. Surgical pericardiectomy was successful in removing the abscess and nidus for septic effusion in this patient, and histopathology of the abscess tissue was suggestive of foreign plant material migration as the nidus for abscess formation. Recheck echocardiogram at the six-month postoperative period showed no recurrence of pericardial effusion or abscessation. Although abscess formation and septic pericarditis secondary to foreign body migration is an uncommon cause for large volume pericardial effusion, this should be considered as a differential particularly in a young and previously healthy dog.
Collapse
Affiliation(s)
- N K Sheehan
- University of Wisconsin Veterinary Medical Teaching Hospital, Madison, WI, 53706, USA
| | - H B Kellihan
- University of Wisconsin Veterinary Medical Teaching Hospital, Madison, WI, 53706, USA.
| | - B Yarnall
- University of Wisconsin Veterinary Medical Teaching Hospital, Madison, WI, 53706, USA
| | - M Graham
- University of Wisconsin Veterinary Medical Teaching Hospital, Madison, WI, 53706, USA
| | - F Moore
- Marshfield Labs, Marshfield, WI, 54449, USA
| |
Collapse
|
27
|
Reimer A, Weedmark K, Petkau A, Peterson CL, Walker M, Knox N, Kent H, Mabon P, Berry C, Tyler S, Tschetter L, Jerome M, Allen V, Hoang L, Bekal S, Clark C, Nadon C, Van Domselaar G, Pagotto F, Graham M, Farber J, Gilmour M. Shared genome analyses of notable listeriosis outbreaks, highlighting the critical importance of epidemiological evidence, input datasets and interpretation criteria. Microb Genom 2019; 5. [PMID: 30648944 PMCID: PMC6412057 DOI: 10.1099/mgen.0.000237] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The persuasiveness of genomic evidence has pressured scientific agencies to supplement or replace well-established methodologies to inform public health and food safety decision-making. This study of 52 epidemiologically defined Listeria monocytogenes isolates, collected between 1981 and 2011, including nine outbreaks, was undertaken (1) to characterize their phylogenetic relationship at finished genome-level resolution, (2) to elucidate the underlying genetic diversity within an endemic subtype, CC8, and (3) to re-evaluate the genetic relationship and epidemiology of a CC8-delimited outbreak in Canada in 2008. Genomes representing Canadian Listeria outbreaks between 1981 and 2010 were closed and manually annotated. Single nucleotide variants (SNVs) and horizontally acquired traits were used to generate phylogenomic models. Phylogenomic relationships were congruent with classical subtyping and epidemiology, except for CC8 outbreaks, wherein the distribution of SNV and prophages revealed multiple co-evolving lineages. Chronophyletic reconstruction of CC8 evolution indicates that prophage-related genetic changes among CC8 strains manifest as PFGE subtype reversions, obscuring the relationship between CC8 isolates, and complicating the public health interpretation of subtyping data, even at maximum genome resolution. The size of the shared genome interrogated did not change the genetic relationship measured between highly related isolates near the tips of the phylogenetic tree, illustrating the robustness of these approaches for routine public health applications where the focus is recent ancestry. The possibility exists for temporally and epidemiologically distinct events to appear related even at maximum genome resolution, highlighting the continued importance of epidemiological evidence.
Collapse
Affiliation(s)
- Aleisha Reimer
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Kelly Weedmark
- 2Health Canada, Bureau of Microbial Hazards, Ottawa, ON, K1A 0K9, Canada
| | - Aaron Petkau
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | | | - Matthew Walker
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Natalie Knox
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Heather Kent
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Philip Mabon
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Chrystal Berry
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Shaun Tyler
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | | | - Morganne Jerome
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Vanessa Allen
- 3Public Health Ontario, Toronto, ON, M5G 1M1, Canada
| | - Linda Hoang
- 4British Columbia Centre for Disease Control, Public Health Microbiology and Reference Laboratory, Vancouver, BC V5Z 4R4, Canada
| | - Sadjia Bekal
- 5Laboratoire de Santé Publique du Québec, Sainte-Anne-de-Bellevue, Québec, H9X 3R5, Canada
| | - Clifford Clark
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Celine Nadon
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | | | - Franco Pagotto
- 2Health Canada, Bureau of Microbial Hazards, Ottawa, ON, K1A 0K9, Canada
| | - Morag Graham
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| | - Jeff Farber
- 6University of Guelph, Guelph, ON, N1G 2W, Canada
| | - Matthew Gilmour
- 1Public Health Agency of Canada, Winnipeg, MB, R3E 3R2, Canada
| |
Collapse
|
28
|
Turgeon R, Koshman S, Youngson E, Har B, Graham M. REAL-WORLD USE OF TICAGRELOR DOES NOT REDUCE MAJOR ADVERSE CARDIOVASCULAR EVENTS, BUT INCREASES MAJOR BLEEDING AND HEALTHCARE VISITS FOR DYSPNEA COMPARED TO CLOPIDOGREL: A CANADIAN REGISTRY STUDY. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
29
|
Chiliza N, Graham M, Wasserman S. Outcomes of HIV-associated pneumocystis pneumonia at a South African referral hospital. Int J Infect Dis 2018. [DOI: 10.1016/j.ijid.2018.04.3625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
30
|
Tyler S, Tyson S, Dibernardo A, Drebot M, Feil EJ, Graham M, Knox NC, Lindsay LR, Margos G, Mechai S, Van Domselaar G, Thorpe HA, Ogden NH. Whole genome sequencing and phylogenetic analysis of strains of the agent of Lyme disease Borrelia burgdorferi from Canadian emergence zones. Sci Rep 2018; 8:10552. [PMID: 30002414 PMCID: PMC6043495 DOI: 10.1038/s41598-018-28908-7] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Accepted: 06/27/2018] [Indexed: 12/19/2022] Open
Abstract
Lyme disease is emerging in southern Canada due to range expansion of the tick vector, followed by invasion of the agent of Lyme disease Borrelia burgdorferi sensu stricto. Strain diversity, as determined by Multi Locus Sequence Typing, occurs in this zone of emergence, and this may have its origins in adaptation to ecological niches, and have phenotypic consequences for pathogenicity and serological test performance. Sixty-four unique strains were cultured from ticks collected in southern Canada and the genomes sequenced using the Illumina MiSeq platform. A maximum likelihood phylogenetic tree of the chromosome revealed two large clades with multiple subclades. Consistent with previous studies on this species, the clades were not geographically defined, and some Canadian strains were highly divergent from previously sequenced US strains. There was evidence for recombination in the chromosome but this did not affect the phylogeny. Analysis of chromosomal genes indicated that these are under intense purifying selection. Phylogenies of the accessory genome and chromosome were congruent. Therefore strain differences identified in the phylogeny of chromosomal genes likely act as a proxy for genetic determinants of phenotypic differences amongst strains that are harboured in the accessory genome. Further studies on health implications of strain diversity are needed.
Collapse
Affiliation(s)
- Shaun Tyler
- Genomics Core Facility, National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, 1015, Arlington St., Winnipeg, Manitoba, Canada
| | - Shari Tyson
- Genomics Core Facility, National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, 1015, Arlington St., Winnipeg, Manitoba, Canada
| | - Antonia Dibernardo
- Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Michael Drebot
- Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Edward J Feil
- Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath, United Kingdom
| | - Morag Graham
- Genomics Core Facility, National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, 1015, Arlington St., Winnipeg, Manitoba, Canada
| | - Natalie C Knox
- Genomics Core Facility, National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, 1015, Arlington St., Winnipeg, Manitoba, Canada
| | - L Robbin Lindsay
- Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Gabriele Margos
- Ludwig Maximilians Universität München, Department for Infectious Diseases and Zoonoses, Munich, Germany.,National Reference Centre for Borrelia, Oberschleissheim and Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
| | - Samir Mechai
- Public Health Risk Sciences Division, National Microbiology Laboratory, Public Health Agency of Canada, Saint-Hyacinthe, Québec, J2S 2M2, Canada
| | - Gary Van Domselaar
- Genomics Core Facility, National Microbiology Laboratory, Public Health Agency of Canada, Canadian Science Centre for Human and Animal Health, 1015, Arlington St., Winnipeg, Manitoba, Canada
| | - Harry A Thorpe
- Department of Biology and Biochemistry, University of Bath, Claverton Down, Bath, United Kingdom
| | - Nick H Ogden
- Public Health Risk Sciences Division, National Microbiology Laboratory, Public Health Agency of Canada, Saint-Hyacinthe, Québec, J2S 2M2, Canada.
| |
Collapse
|
31
|
Abstract
Phase change materials (PCMs) allow the storage of large amounts of latent heat during phase transition. They have the potential to both increase the efficiency of renewable energies such as solar power through storage of excess energy, which can be used at times of peak demand; and to reduce overall energy demand through passive thermal regulation. 198.3 million tons of oil equivalent were used in the EU in 2013 for heating. However, bulk PCMs are not suitable for use without prior encapsulation. Encapsulation in a shell material provides benefits such as protection of the PCM from the external environment and increased specific surface area to improve heat transfer. This review highlights techniques for the encapsulation of both organic and inorganic PCMs, paying particular attention to nanoencapsulation (capsules with sizes <1 μm). We also provide insight on future research, which should focus on (i) the development of multifunctional shell materials to improve lifespan and thermal properties and (ii) advanced mass manufacturing techniques for the economically viable production of PCM capsules, making it possible to utilize waste heat in intelligent passive thermal regulation systems, employing controlled, "on demand" energy release/uptake.
Collapse
Affiliation(s)
- E M Shchukina
- Stephenson Institute for Renewable Energy, Department of Chemistry, University of Liverpool, Crown Street, L69 7ZD, Liverpool, UK.
| | | | | | | |
Collapse
|
32
|
De Moel-Mandel C, Graham M, Taket A. Medication abortion provision in the primary health care setting of regional Victoria, Australia. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx186.355] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - M Graham
- Deakin University, Melbourne, Australia
| | - A Taket
- Deakin University, Melbourne, Australia
| |
Collapse
|
33
|
Graham M, Taket A. Primary care nurses’ potential role in medication abortion provision in regional Victoria, Australia. Eur J Public Health 2017. [DOI: 10.1093/eurpub/ckx186.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M Graham
- Deakin University, Melbourne, Australia
| | - A Taket
- Deakin University, Melbourne, Australia
| |
Collapse
|
34
|
Dumortier P, Durodié F, Blackman T, Graham M, Helou W, Lerche E, Monakhov I, Noble C, Wooldridge E, Goulding R, Jacquet P, Kaufman M. Commissioning and first results of the reinstated JET ICRF ILA. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.05.050] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
35
|
Haim MS, Di Gregorio S, Galanternik L, Lubovich S, Vázquez M, Bharat A, Zaheer R, Golding GR, Graham M, Van Domselaar G, Cardona ST, Mollerach M. First description of rpsJ and mepA mutations associated with tigecycline resistance in Staphylococcus aureus isolated from a cystic fibrosis patient during antibiotic therapy. Int J Antimicrob Agents 2017; 50:739-741. [PMID: 29038088 DOI: 10.1016/j.ijantimicag.2017.10.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Revised: 10/04/2017] [Accepted: 10/07/2017] [Indexed: 11/28/2022]
Affiliation(s)
- M S Haim
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Microbiología, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - S Di Gregorio
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Microbiología, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
| | - L Galanternik
- Microbiología, Laboratorio Central, Hospital de Niños 'Dr Ricardo Gutiérrez', Buenos Aires, Argentina
| | - S Lubovich
- Centro Respiratorio, Hospital de Niños 'Dr Ricardo Gutiérrez', Buenos Aires, Argentina
| | - M Vázquez
- Microbiología, Laboratorio Central, Hospital de Niños 'Dr Ricardo Gutiérrez', Buenos Aires, Argentina
| | - A Bharat
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
| | - R Zaheer
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada
| | - G R Golding
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada; Department of Medical Microbiology & Infectious Diseases, University of Manitoba, Winnipeg, Canada
| | - M Graham
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada; Department of Medical Microbiology & Infectious Diseases, University of Manitoba, Winnipeg, Canada
| | - G Van Domselaar
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada; Department of Medical Microbiology & Infectious Diseases, University of Manitoba, Winnipeg, Canada
| | - S T Cardona
- Department of Medical Microbiology & Infectious Diseases, University of Manitoba, Winnipeg, Canada; Department of Microbiology, University of Manitoba, Winnipeg, Canada
| | - M Mollerach
- Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Microbiología, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.
| |
Collapse
|
36
|
Seyedin S, Mallak N, Mott S, Menda Y, Graham M, Anderson C. The Role of 3 Month PET-CT After Definitive Radiation for Laryngeal Carcinoma. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1487] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
37
|
Malerba A, Klein P, Bachtarzi H, Jarmin S, Cordova G, Ferry A, Strings V, Espinoza MP, Mamchaoui K, Blumen S, Guily JLS, Mouly V, Graham M, Butler-Browne G, Suhy D, Trollet C, Dickson G. Gene therapy for oculopharyngeal muscular dystrophy. Neuromuscul Disord 2017. [DOI: 10.1016/j.nmd.2017.06.541] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
38
|
Griffiths E, Dooley D, Graham M, Van Domselaar G, Brinkman FSL, Hsiao WWL. Context Is Everything: Harmonization of Critical Food Microbiology Descriptors and Metadata for Improved Food Safety and Surveillance. Front Microbiol 2017; 8:1068. [PMID: 28694792 PMCID: PMC5483436 DOI: 10.3389/fmicb.2017.01068] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Accepted: 05/29/2017] [Indexed: 11/18/2022] Open
Abstract
Globalization of food networks increases opportunities for the spread of foodborne pathogens beyond borders and jurisdictions. High resolution whole-genome sequencing (WGS) subtyping of pathogens promises to vastly improve our ability to track and control foodborne disease, but to do so it must be combined with epidemiological, clinical, laboratory and other health care data (called “contextual data”) to be meaningfully interpreted for regulatory and health interventions, outbreak investigation, and risk assessment. However, current multi-jurisdictional pathogen surveillance and investigation efforts are complicated by time-consuming data re-entry, curation and integration of contextual information owing to a lack of interoperable standards and inconsistent reporting. A solution to these challenges is the use of ‘ontologies’ - hierarchies of well-defined and standardized vocabularies interconnected by logical relationships. Terms are specified by universal IDs enabling integration into highly regulated areas and multi-sector sharing (e.g., food and water microbiology with the veterinary sector). Institution-specific terms can be mapped to a given standard at different levels of granularity, maximizing comparability of contextual information according to jurisdictional policies. Fit-for-purpose ontologies provide contextual information with the auditability required for food safety laboratory accreditation. Our research efforts include the development of a Genomic Epidemiology Ontology (GenEpiO), and Food Ontology (FoodOn) that harmonize important laboratory, clinical and epidemiological data fields, as well as existing food resources. These efforts are supported by a global consortium of researchers and stakeholders worldwide. Since foodborne diseases do not respect international borders, uptake of such vocabularies will be crucial for multi-jurisdictional interpretation of WGS results and data sharing.
Collapse
Affiliation(s)
- Emma Griffiths
- Department of Molecular Biology and Biochemistry, Simon Fraser University, VancouverBC, Canada
| | - Damion Dooley
- Department of Pathology and Laboratory Medicine, University of British Columbia, VancouverBC, Canada
| | - Morag Graham
- National Microbiology Laboratory, Public Health Agency of Canada, WinnipegMB, Canada.,Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, WinnipegMB, Canada
| | - Gary Van Domselaar
- National Microbiology Laboratory, Public Health Agency of Canada, WinnipegMB, Canada.,Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, WinnipegMB, Canada
| | - Fiona S L Brinkman
- Department of Molecular Biology and Biochemistry, Simon Fraser University, VancouverBC, Canada
| | - William W L Hsiao
- Department of Pathology and Laboratory Medicine, University of British Columbia, VancouverBC, Canada.,British Columbia Centre for Disease Control Public Health Laboratory, VancouverBC, Canada
| |
Collapse
|
39
|
Petkau A, Mabon P, Sieffert C, Knox NC, Cabral J, Iskander M, Iskander M, Weedmark K, Zaheer R, Katz LS, Nadon C, Reimer A, Taboada E, Beiko RG, Hsiao W, Brinkman F, Graham M, Van Domselaar G. SNVPhyl: a single nucleotide variant phylogenomics pipeline for microbial genomic epidemiology. Microb Genom 2017; 3:e000116. [PMID: 29026651 PMCID: PMC5628696 DOI: 10.1099/mgen.0.000116] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2017] [Accepted: 04/12/2017] [Indexed: 11/18/2022] Open
Abstract
The recent widespread application of whole-genome sequencing (WGS) for microbial disease investigations has spurred the development of new bioinformatics tools, including a notable proliferation of phylogenomics pipelines designed for infectious disease surveillance and outbreak investigation. Transitioning the use of WGS data out of the research laboratory and into the front lines of surveillance and outbreak response requires user-friendly, reproducible and scalable pipelines that have been well validated. Single Nucleotide Variant Phylogenomics (SNVPhyl) is a bioinformatics pipeline for identifying high-quality single-nucleotide variants (SNVs) and constructing a whole-genome phylogeny from a collection of WGS reads and a reference genome. Individual pipeline components are integrated into the Galaxy bioinformatics framework, enabling data analysis in a user-friendly, reproducible and scalable environment. We show that SNVPhyl can detect SNVs with high sensitivity and specificity, and identify and remove regions of high SNV density (indicative of recombination). SNVPhyl is able to correctly distinguish outbreak from non-outbreak isolates across a range of variant-calling settings, sequencing-coverage thresholds or in the presence of contamination. SNVPhyl is available as a Galaxy workflow, Docker and virtual machine images, and a Unix-based command-line application. SNVPhyl is released under the Apache 2.0 license and available at http://snvphyl.readthedocs.io/ or at https://github.com/phac-nml/snvphyl-galaxy.
Collapse
Affiliation(s)
- Aaron Petkau
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | - Philip Mabon
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | - Cameron Sieffert
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | - Natalie C Knox
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | - Jennifer Cabral
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | | | - Mark Iskander
- 2University of Manitoba, Winnipeg, MB R3T 2N2, Canada
| | - Kelly Weedmark
- 3Health Canada - Bureau of Microbial Hazards, Ottawa, ON K1A 0K9, Canada
| | - Rahat Zaheer
- 4Lethbridge Research and Development Centre, Lethbridge, AB T1J 4B1, Canada
| | - Lee S Katz
- 5Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
| | - Celine Nadon
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | - Aleisha Reimer
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | - Eduardo Taboada
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | | | - William Hsiao
- 7BC Public Health Microbiology and Reference Laboratory, Vancouver, BC V5Z 4R4, Canada
| | | | - Morag Graham
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| | - Gary Van Domselaar
- 1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada
| |
Collapse
|
40
|
Demczuk WHB, Martin I, Hoang L, Van Caeseele P, Lefebvre B, Horsman G, Haldane D, Gubbay J, Ratnam S, German G, Daley Bernier J, Strudwick L, McGeer A, Zhanel GG, Van Domselaar G, Graham M, Mulvey MR. Phylogenetic analysis of emergent Streptococcus pneumoniae serotype 22F causing invasive pneumococcal disease using whole genome sequencing. PLoS One 2017; 12:e0178040. [PMID: 28531208 PMCID: PMC5439729 DOI: 10.1371/journal.pone.0178040] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2016] [Accepted: 05/08/2017] [Indexed: 12/14/2022] Open
Abstract
Since implementation of the 13-valent polyvalent conjugate vaccine (PCV13) in Canada during 2010, the proportion of PCV13 serotypes causing invasive pneumococcal disease (IPD) has declined from 55% (n = 1492) in 2010 to 31% (n = 764) in 2014. A concurrent increase of non-PCV13 serotypes has occurred and 22F has become the most prevalent serotype in Canada increasing from 7% (n = 183) to 11% (n = 283). Core single nucleotide variant phylogenetic analysis was performed on 137 Streptococcus pneumoniae serotype 22F isolates collected across Canada from 2005-2015. Six phylogenetic lineages (n = 117) were identified among a serotype 22F/ST433 clonal complex (CC), including a recently expanding erythromycin-resistant clone. Erythromycin-resistance was observed in 25 isolates possessing ermB, mef or a 23S rRNA A2061G point mutation; 2 penicillin-resistant isolates had recombinant pbp1a, pbp2a and/or pbp2x; 3 tetracycline-resistant isolates contained tetM; and 1 isolate was multidrug-resistant. Virulence factor analysis indicated a high level of homogeneity among the 22F/ST433 clonal complex strains. A group of 6 phylogenetic outlier strains had differing MLST, antimicrobial resistance and molecular profiles suggestive of capsule switching events. While capsule switch events among S. pneumoniae serotype 22F has been observed, increasing prevalence of S. pneumoniae serotype 22F can be attributed to an evolving homogenous clone expanding nationally through local transmission events.
Collapse
Affiliation(s)
- Walter H. B. Demczuk
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Irene Martin
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Linda Hoang
- British Columbia Centre for Disease Control, Vancouver, British, Canada
| | | | - Brigitte Lefebvre
- Laboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, Québec, Canada
| | - Greg Horsman
- Saskatchewan Disease Control Laboratory, Regina, Saskatchewan, Canada
| | - David Haldane
- Queen Elizabeth II Health Science Centre, Halifax, Nova Scotia, Canada
| | | | - Sam Ratnam
- Newfoundland Public Health Laboratory, St. John’s, Newfoundland and Labrador, Canada
| | - Gregory German
- Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, Canada
| | | | | | - Allison McGeer
- Toronto Invasive Bacterial Diseases Network, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - George G. Zhanel
- Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada
| | - Gary Van Domselaar
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
- Science Technology Cores and Services Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Morag Graham
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
- Science Technology Cores and Services Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
| | - Michael R. Mulvey
- National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
- * E-mail:
| |
Collapse
|
41
|
Alfa MJ, Strang D, Tappia PS, Graham M, Van Domselaar G, Forbes JD, Laminman V, Olson N, DeGagne P, Bray D, Murray BL, Dufault B, Lix LM. A randomized trial to determine the impact of a digestion resistant starch composition on the gut microbiome in older and mid-age adults. Clin Nutr 2017; 37:797-807. [PMID: 28410921 DOI: 10.1016/j.clnu.2017.03.025] [Citation(s) in RCA: 83] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2016] [Revised: 03/21/2017] [Accepted: 03/22/2017] [Indexed: 12/14/2022]
Abstract
BACKGROUND The elderly often have a diet lacking resistant starch (RS) which is thought to lead to gut microbiome dysbiosis that may result in deterioration of gut colonocytes. OBJECTIVE The primary objective was to assess if elderly (ELD; ≥ 70 years age) had microbiome dysbiosis compared to mid-age (MID; 30-50 years age) adults and then determine the impact of daily consumption of MSPrebiotic® (a RS) or placebo over 3 months on gut microbiome composition. Secondary objectives included assessment of stool short-chain fatty acids (SCFA) and inflammatory markers in ELD and MID Canadian adults. DESIGN This was a prospective, placebo controlled, randomized, double-blinded study. Stool was collected at enrollment and 6, 10 and 14 weeks after randomization to placebo or MSPrebiotic®. Microbiome analysis was done using 16S rRNA sequencing of DNA extracted from stool. SCFA analysis of stool was performed using gas chromatography. RESULTS There were 42 ELD and 42 MID participants randomized to either placebo or MSPrebiotic® who completed the study. There was significantly higher abundance of Proteobacteria (Escherichia coli/Shigella) in ELD compared to MID at enrollment (p < 0.001) that was not observed after 12 weeks of MSPrebiotic® consumption. There was a significant increase in Bifidobacterium in both ELD and MID compared to placebo (p = 0.047 and 0.006, respectively). There was a small but significant increase in the stool SCFA butyrate levels in the ELD on MSPrebiotic® versus placebo. CONCLUSIONS The study data demonstrated that MSPrebiotic® meets the criteria of a prebiotic and can stimulate an increased abundance of endogenous Bifidobacteria in both ELD and MID without additional probiotic supplementation. MSPrebiotic® consumption also eliminated the dysbiosis of gut Proteobacteria observed in ELD at baseline. CLINICAL TRIAL REGISTRY NUMBER NCT01977183 listed on NIH website: ClinicalTrials.gov. The full trial protocol is available on request from the corresponding author. NUCLEOTIDE SEQUENCE ACCESSION NUMBERS The 16S rRNA sequencing data and metadata generated in this study have been submitted to the NCBI Sequence Read Archive (SRA: http://www.ncbi.nlm.nih.gov/bioproject/381931).
Collapse
Affiliation(s)
- Michelle J Alfa
- St. Boniface Research Centre, Canada; Dept of Medical Microbiology University of Manitoba, Canada.
| | | | | | - Morag Graham
- Dept of Medical Microbiology University of Manitoba, Canada; National Microbiology Laboratory, Public Health Agency of Canada, Canada
| | - Gary Van Domselaar
- Dept of Medical Microbiology University of Manitoba, Canada; National Microbiology Laboratory, Public Health Agency of Canada, Canada
| | - Jessica D Forbes
- Dept of Medical Microbiology University of Manitoba, Canada; National Microbiology Laboratory, Public Health Agency of Canada, Canada
| | - Vanessa Laminman
- National Microbiology Laboratory, Public Health Agency of Canada, Canada
| | | | | | | | | | - Brenden Dufault
- George and Fay Yee Centre for Healthcare Innovation, Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada
| | - Lisa M Lix
- George and Fay Yee Centre for Healthcare Innovation, Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada
| |
Collapse
|
42
|
Malerba A, Klein P, Bachtarzi H, Jarmin SA, Cordova G, Ferry A, Strings V, Espinoza MP, Mamchaoui K, Blumen SC, St Guily JL, Mouly V, Graham M, Butler-Browne G, Suhy DA, Trollet C, Dickson G. PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nat Commun 2017; 8:14848. [PMID: 28361972 PMCID: PMC5380963 DOI: 10.1038/ncomms14848] [Citation(s) in RCA: 49] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 02/07/2017] [Indexed: 01/14/2023] Open
Abstract
Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant, late-onset muscle disorder characterized by ptosis, swallowing difficulties, proximal limb weakness and nuclear aggregates in skeletal muscles. OPMD is caused by a trinucleotide repeat expansion in the PABPN1 gene that results in an N-terminal expanded polyalanine tract in polyA-binding protein nuclear 1 (PABPN1). Here we show that the treatment of a mouse model of OPMD with an adeno-associated virus-based gene therapy combining complete knockdown of endogenous PABPN1 and its replacement by a wild-type PABPN1 substantially reduces the amount of insoluble aggregates, decreases muscle fibrosis, reverts muscle strength to the level of healthy muscles and normalizes the muscle transcriptome. The efficacy of the combined treatment is further confirmed in cells derived from OPMD patients. These results pave the way towards a gene replacement approach for OPMD treatment. Oculopharyngeal muscular dystrophy is caused by trinucleotide repeat expansions in the PABPN1 gene. Here the authors use AAV-based gene therapy to knockdown the mutant gene and replace it with a wild-type allele, and show effectiveness in mice and in patient cells.
Collapse
Affiliation(s)
- A Malerba
- School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, TW20 0EX Surrey, UK
| | - P Klein
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France
| | - H Bachtarzi
- School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, TW20 0EX Surrey, UK
| | - S A Jarmin
- School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, TW20 0EX Surrey, UK
| | - G Cordova
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France
| | - A Ferry
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France.,Sorbonne Paris Cité, Université Paris Descartes, 75006 Paris, France
| | - V Strings
- Benitec Biopharma, 3940 Trust Way, Hayward, California 94545, USA
| | - M Polay Espinoza
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France
| | - K Mamchaoui
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France
| | - S C Blumen
- Department of Neurology, Hillel Yaffe Medical Center, Hadera and Rappaport Faculty of Medicine, The Technion, 1 Efron Street, Haifa 31096, Israel
| | - J Lacau St Guily
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France.,Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and University Pierre-et-Marie-Curie, Paris VI, Tenon Hospital, Assistance Publique des Hopitaux de Paris, 75252 Paris, France
| | - V Mouly
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France
| | - M Graham
- Benitec Biopharma, 3940 Trust Way, Hayward, California 94545, USA
| | - G Butler-Browne
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France
| | - D A Suhy
- Benitec Biopharma, 3940 Trust Way, Hayward, California 94545, USA
| | - C Trollet
- Sorbonne Universités, UPMC Univ Paris 06, UM76, INSERM U974, Institut de Myologie, CNRS FRE3617, 47 bd de l'Hôpital, 75013 Paris, France
| | - G Dickson
- School of Biological Sciences, Royal Holloway, University of London, Egham Hill, Egham, TW20 0EX Surrey, UK
| |
Collapse
|
43
|
Schneider B, Miller KD, Badve S, O'Neil B, Helft P, Chitambar C, Falkson C, Nanda R, McCormick M, Danso M, Blaya M, Langdon R, Lippman M, Paplomata E, Walling R, Thompson M, Robin E, Aggarwal L, Shalaby I, Canfield V, Adesunloye B, Lee T, Daily K, Ma C, Erban J, Radhakrishnan N, Bruetman D, Graham M, Reddy NA, Lynce FC, Radovich M. Abstract OT3-04-01: BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot3-04-01] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: About 1/3 of patients with TNBC who receive preoperative therapy will experience a pathological complete response (pCR). Patients with residual disease have a markedly inferior overall survival (OS) compared to those who experience pCR. Recently, the CREATE-X trial demonstrated an improvement in disease free survival (DFS) and OS for post-neoadjuvant capecitebine; although the addition of capecitebine to standard therapy has not previously improved outcome across other non-selected adjuvant or neo-adjuvant trials. Prior data have also demonstrated that the residual tumors are genomically diverse and that these genetic changes are reflected at time of relapse.
Trial Design: This trial is a randomized phase II trial to determine whether a genomically guided therapy in the setting of incomplete response to standard neoadjuvant therapy will improve outcomes compared to standard of care. DNA from archived tumor samples collected at the time of surgery will be extracted and sequenced. The sequencing data will be interrogated for known genomic drivers of sensitivity or resistance to existing FDA approved agents. A cancer genomic tumor board (CGTB) will consider the genomic data along with the patient's prior treatment history, toxicities, and comorbidities and select the optimal therapy. Participants with a CGTB recommendation will be randomized to Experimental Arm A (genomically directed monotherapy) or Control Arm B (standard of care). Participants may have no CGTB recommendation either because sequencing did not identify a matched drug or because the drug was contraindicated and will be assigned to Control Arm B.
Eligibility criteria: Patients must have histologically confirmed TNBC with completion of all definitive local therapy and no evidence of metastatic disease. There must be significant residual disease characterized by >2cm primary tumor, or lymph node positivity or RCB classification II or III. An FFPE tumor block with tumor cellularity >20% is required. All patients must have completed preoperative chemotherapy including a taxane or anthracycline or both.
Specific aims: The Primary Aim is to compare 2-year DFS with a genomically directed therapy vs. standard of care. Secondary Aims include 1-year DFS, 5-year OS, collection of archival specimens for correlative studies, and to describe toxicities. Exploratory Aims are to describe the evolution of genomically directed therapies during the course of the study and to evaluate the drug specific effect on efficacy and toxicity.
Statistical methods: In order to detect an improvement in the fraction of patients free from disease at 2-year from 40% in the control Arm B to 63.2% in the genomically directed Experimental Arm A (corresponding to an HR=0.5), 136 participants will have 80% power to detect a difference in DFS using a two-side log-rank test with 0.05 level of significance.
Present accrual/target accrual: 38 accrued of 136 to be randomized.
Citation Format: Schneider B, Miller KD, Badve S, O'Neil B, Helft P, Chitambar C, Falkson C, Nanda R, McCormick M, Danso M, Blaya M, Langdon R, Lippman M, Paplomata E, Walling R, Thompson M, Robin E, Aggarwal L, Shalaby I, Canfield V, Adesunloye B, Lee T, Daily K, Ma C, Erban J, Radhakrishnan N, Bruetman D, Graham M, Reddy NA, Lynce FC, Radovich M. BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT3-04-01.
Collapse
Affiliation(s)
- B Schneider
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - KD Miller
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - S Badve
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - B O'Neil
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - P Helft
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - C Chitambar
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - C Falkson
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - R Nanda
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - M McCormick
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - M Danso
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - M Blaya
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - R Langdon
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - M Lippman
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - E Paplomata
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - R Walling
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - M Thompson
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - E Robin
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - L Aggarwal
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - I Shalaby
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - V Canfield
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - B Adesunloye
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - T Lee
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - K Daily
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - C Ma
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - J Erban
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - N Radhakrishnan
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - D Bruetman
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - M Graham
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - NA Reddy
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - FC Lynce
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| | - M Radovich
- Indiana University Simon Cancer Center; Medical College of Wisconsin; University of Alabama Birmingham; University of Chicago; Meritus Center for Clinical Research; Virginia Oncology Associates; Memorial Cancer Center; Nebraska Methodist Hospital; University of Miami; Winship Cancer Institute of Emory University; Community Regional Cancer Care; Aurora Health Care; Community Healthcare System; Fort Wayne Medical Oncology and Hematology; Joe Arrington Cancer Research and Treatment Center; Mercy Clinic Oklahoma Communities; IU Health Arnett; IU Health Goshen Center for Cancer Care; Pinnacle Health Cancer Center; University of Florida; Washington University at St. Louis; Tufts Medical Center; University of Cincinnati; Erlanger Health System; Community Hospitals of Anderson and Madison Co; Georgetown University
| |
Collapse
|
44
|
Malerba A, Klein P, Bachtarzi H, Jarmin S, Ferry A, Graham M, Strings V, Butler-Browne G, Suhy D, Dickson G, Trollet C. Gene replacement therapy as a novel approach for the treatment of oculopharyngeal muscular dystrophy. Neuromuscul Disord 2016. [DOI: 10.1016/j.nmd.2016.06.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
45
|
Mrkobrada M, Hill M, Chan M, Sigamani A, Cowan D, Kurz A, Sessler D, Jacka M, Graham M, Dasgupta M, Dunlop V, Emery D, Gulka I, Guyatt G, Heels-Ansdell D, Murkin J, Pettit S, Sahlas D, Sharma M, Sharma M, Srinathan S, St John P, Tsai S, Gelb A, O’Donnell M, Siu D, Chiu P, Sharath V, George A, Devereaux P. Covert stroke after non-cardiac surgery: a prospective cohort study. Br J Anaesth 2016; 117:191-7. [DOI: 10.1093/bja/aew179] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/30/2016] [Indexed: 11/13/2022] Open
|
46
|
McAlister FA, Jacka M, Graham M, Youngson E, Cembrowski G, Bagshaw SM, Pannu N, Townsend DR, Srinathan S, Alonso-Coello P, Devereaux PJ. The prediction of postoperative stroke or death in patients with preoperative atrial fibrillation undergoing non-cardiac surgery: a VISION sub-study. J Thromb Haemost 2015; 13:1768-75. [PMID: 26270168 DOI: 10.1111/jth.13110] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2015] [Accepted: 07/07/2015] [Indexed: 11/30/2022]
Abstract
BACKGROUND The optimal means of pre-operative risk stratification in patients with atrial fibrillation (AF) is uncertain. OBJECTIVE To examine the accuracy of AF thromboembolic risk models (the CHADS2, CHA2DS2-VASc, and R2CHADS2 scores) for predicting 30-day stroke and/or all-cause mortality after non-cardiac surgery in patients with preoperative AF, and to compare these risk scores with the Revised Cardiac Risk Index (RCRI). PATIENTS/METHODS A multicentre (8 countries, 2007-2011) prospective cohort study of patients ≥ 45 years of age undergoing inpatient non-cardiac surgery, who were followed until 30 days after surgery. We calculated c-statistics for each risk prediction model and net reclassification improvements (NRIs) compared with the RCRI. RESULTS The 961 patients with preoperative AF were at higher risk of any cardiovascular event in the 30 days postoperatively compared with the 13 001 patients without AF: 26.6% vs. 9.0%; adjusted odds ratio, 1.58; 95% confidence interval [CI], 1.33-1.88. All thromboembolic risk scores predicted postoperative death just as well as the RCRI (with c-indices between 0.67 and 0.72). Compared with the RCRI (which had a c-index of 0.64 for 30-day stroke/death), the CHADS2 (c-index, 0.67; NRI, 0.31; 95% CI, 0.02-0.61) significantly improved postoperative stroke/mortality risk prediction, largely due to improved discrimination of patients who did not subsequently have an event. CONCLUSIONS In AF patients, the three thromboembolic risk scores performed similarly to the RCRI in predicting death within 30 days and the CHADS2 score was the best predictor of postoperative stroke/death regardless of type of surgery.
Collapse
Affiliation(s)
- F A McAlister
- Patient Health Outcomes Research and Clinical Effectiveness Unit, Edmonton, AB, Canada
- Division of General Internal Medicine, Department of Medicine, Edmonton, AB, Canada
| | - M Jacka
- Division of Critical Care Medicine, Department of Medicine, Edmonton, AB, Canada
| | - M Graham
- Division of Cardiology, Department of Medicine, Edmonton, AB, Canada
| | - E Youngson
- Patient Health Outcomes Research and Clinical Effectiveness Unit, Edmonton, AB, Canada
| | - G Cembrowski
- Division of Medical Biochemistry, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada
| | - S M Bagshaw
- Division of Critical Care Medicine, Department of Medicine, Edmonton, AB, Canada
| | - N Pannu
- Division of Critical Care Medicine, Department of Medicine, Edmonton, AB, Canada
| | - D R Townsend
- Division of Critical Care Medicine, Department of Medicine, Edmonton, AB, Canada
| | - S Srinathan
- Department of Surgery, University of Manitoba, Winnipeg, MB, Canada
| | - P Alonso-Coello
- Iberoamerican Cochrane Center, Biomedical Research Institute Sant Pau (IIB-Sant Pau), CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain
| | - P J Devereaux
- Departments of Clinical Epidemiology and Biostatistics and Medicine, The Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada
| |
Collapse
|
47
|
Shahandeh A, Purushothuman S, Martin K, Graham M, Johnstone D, Milward E. Anti-oxidant Phytochemicals As Potential Treatments For Age-Related Macular Degeneration. ACTA ACUST UNITED AC 2015. [DOI: 10.14302/issn.2471-2140.jaa-14-616] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
48
|
Plumley C, Leithead W, Jamieson P, Bossanyi E, Graham M. Comparison of individual pitch and smart rotor control strategies for load reduction. ACTA ACUST UNITED AC 2014. [DOI: 10.1088/1742-6596/524/1/012054] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
49
|
Earle N, Smith W, Crawford J, Love D, Hayes I, Graham M, Donoghue T, Hood M, Stiles M, Skinner J. The prevalence of emerging genotypic risk factors in patients with long QT syndrome. Heart Lung Circ 2014. [DOI: 10.1016/j.hlc.2014.07.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
50
|
Skinner J, Crawford J, Waddell-Smith K, Earle N, Donoghue T, Graham M, Hayes I, Stiles M, Smith W, Love D. Development of the New Zealand cardiac inherited disease registry. Heart Lung Circ 2014. [DOI: 10.1016/j.hlc.2014.07.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|